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ABSTRACT 
Pharmaceutical cocrystals use principles of crystal engineering for the design of 
crystalline forms of drugs and can improve their solubility, bioavailability, stability and 
other important properties without changing the efficacy of the drug. Herein reported are 
pharmaceutical cocrystals of two API’s, caffeine and Pentoxifylline. 
Research has indicated that caffeine has the ability to reverse Aβ plaque deposition in the 
brain (believed to be the primary cause of Alzheimer’s pathogenesis) and thus revert 
memory and improve cognitive impairment. But owing to the fast absorption rate and 
short half life, a controlled release formulation of caffeine would be clinically beneficial. 
Thus, novel cocrystals of caffeine are presented with varying solubilities with respect to 
caffeine. The pharmaceutical cocrystals of caffeine used herein include: caffeine·cyanuric 
acid monohydrate, caffeine·syringic acid tetrahydrate, caffeine·chlorogenic acid and 
caffeine·catechin hydrate. Three caffeine cocrystals were prepared in our lab previously 
which include caffeine·ferulic acid, caffeine·ethyl gallate dihydrate and caffeine·caffeic 
acid. In addition, six caffeine cocrystal forms were reproduced from the literature and 
included in the solubility study: caffeine· quercetin, caffeine·salicylic acid, caffeine·1-
hydroxy-2-napthoic acid, caffeine·gallic acid hemihydrate, caffeine·ellagic acid 
monohydrate and caffeine· coumaric acid. Dissolution studies were performed in aqueous 
media at room temperature. All of the cocrystals decreased the solubility of caffeine with 
the highest being a 278 fold decrease in the solubility of caffeine. Analysis of melting 
point, crystal packing efficiency and solubility of cocrystal former with solubility was 
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also done to determine if they influenced the solubility. Presented herein are the results of 
the analyses. It was seen that solubility of the cocrystal former had no effect on the 
decrease in cocrystal solubility. Moreover melting point and solubility of the cocrystal 
could not be correlated probably due to the variability in the cocrystal formers. Crystal 
packing efficiency though did not show a high correlation with solubility but it was seen 
that highest solubility achieved by pure caffeine achieved the lowest crystal packing 
efficiency and vice versa suggesting its role in cocrystal solubility. 
Pentoxifylline is contraindicated for its use in autism. But owing to high solubility of the 
drug, a less soluble form of the drug would help in decreasing the half life and thereby 
help in forming a sustained form of the drug by modifying the inherent solubility of the 
API. Here, novel cocrystals of Pentoxifylline are presented with varying solubilities with 
respect to the API. The pharmaceutical cocrystals used herein include: pentoxifylline· 
benzoic acid, pentoxifylline·1-hydroxy-2-napthoic acid, pentoxifylline·salicylic acid, 
pentoxifylline·gallic acid, pentoxifylline. salicylamide, pentoxifylline·coumaric acid, 
pentoxifylline·caffeic acid and pentoxifylline·catechin hydrate. Dissolution studies were 
also performed in aqueous media at room temperature. All of the cocrystals decreased the 
solubility of Pentoxifylline with the highest being a 99 fold decrease in the solubility with 
pentoxifylline·coumaric acid. On analyzing melting point, crystal packing efficiency and 
relation of solubility of cocrystal former with solubility of cocrystal, as was done in the 
case of caffeine, the parameters showed no effect on solubility of the cocrystal.  
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1. CHAPTER 1: INTRODUCTION 
 
1.1. Crystal Engineering 
Crystal Engineering, a part of organic solid state chemistry was introduced in 1955 by 
Pepinsky 
1
 and established by Schmidt 
2   
through the topochemical reactions on cinnamic 
acid. Though Schmidt and his contemporaries worked on this newly formed field to 
discover structures with reference to assembly of molecules and thereby stability in 
structures with the help of X-ray crystallography, this field gained prominence from the 
1900’s with the advent of metal organics, organometallics 4 and organic solids and since 
then the field of crystal engineering has advanced resulting in greater understanding of 
how to design viable crystalline forms.
 1, 2, 3
 Gautam Desiraju, a pioneer in the field, 
defined crystal engineering as “the understanding of intermolecular interactions in the 
context of crystal packing and in the utilization of such understanding in the design of 
new solids with desired physical and chemical properties”. 5 Intermolecular forces play a 
vital role in crystal engineering and the most important being non covalent interactions 
which includes hydrogen bonding, Van der Waals forces, hydrophobic forces, 
electrostatic forces and п- п interactions , which further help in crystal packing and self 
assembly. 
3, 5, 6
 Crystal engineering is also based on the principle of understanding motifs 
present in a molecule, leading to the formation of “synthons” using  non covalent 
interactions. The term “synthons” as defined by Corey 7 are “structural units within 
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molecules which can be formed and/or assembled by known or conceivable synthetic 
operations”. Desiraju further utilized this concept to define “supramolecular synthons” 
which are defined as “structural units within supermolecules which can be formed and/or 
assembled by known or conceivable intermolecular interactions” 5(b) in the context of a 
set of compounds known as “Cocrystals”. Supramolecular synthons are categorized 
further into 2 classes (a) supramolecular homosynthons:  composed of identical self-
complementary functionalities (b) supramolecular heterosynthons: composed of different 
but complementary functionalities. 
19(a)
 Figure 1.1(a) illustrates a supramolecular 
homosynthon, usually formed between similar types of functional groups and in this case 
between two carboxylic acid molecules to form a dimer and 1.1(b) illustrates a 
supramolecular heterosynthon, usually formed between competing and complementary 
functional groups,  and in this case between a carboxylic acid and amide.  
 
                (a)                   (b)   
Figure 1.1. (a) A supramolecular homosynthon is formed between identical 
functional groups, in this case between two carboxylic acid moieties to form a dimer.    
(b) A supramolecular heterosynthon is formed between complementary but 
different functional groups, in this case between carboxylic acid and amide moieties. 
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1.2. Cocrystals 
Cocrystals, 
8, 9 
a class of compounds for which the principles of crystal engineering are 
utilized, have gained a lot of recent attention owing to their amenability to design and 
their ability to tailor physiochemical properties. 
19, 20
 They represent a class of 
compounds with huge potential and play an important part in chemistry and 
pharmaceuticals especially in the field of non linear optics, purification, polymorphism 
26
, 
chiral separation, discovery of persistent synthons 
27
 and also modifying physicochemical 
properties of API’s. 19, 20  
As the properties of a compound depends on the arrangement of the atoms in the crystal 
structure, designing “crystals with a purpose” and thereby modifying its properties has 
resulted in the development of cocrystals.  They are a “long known but little studied” set 
of compounds which constitute only c.a. 0.5% of the Cambridge Structural Database. 
This class of compounds was popularized by Etter. 
8(a) 
The first cocrystal synthesized was 
quinhydrone which is a 1:1 cocrystal between benzoquinone and hydroquinone as 
illustrated in Figure 1.2 and was made by Wohler in 1844. 
10  
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Figure 1.2. The first cocrystal, Quinhydrone was reported in 1844. It is a 1:1 
cocrystal between benzoquinone and hydroquinone (CSD Refcode : QUIDON). 
Following this, Hoogsten in 1963 synthesized a complex between 1-methyl thymine and 
1-methyl adenine as seen in DNA base pairing and used the term “cocrystal “for the first 
time. 
11
 Figure 1.3 illustrates Hoogsten’s base pairing in the complex. 
 
 
Figure 1.3. Hoogsten’s “cocrystal” between1-methyl adenine and 1-methyl thymine 
forms a supramolecular heterosynthon (CSD Refcode : MTHMAD). 
Probably the most prominent biological example of a cocrystal is the base pairing 
observed in DNA 
11(c)
 which shows a strong hydrogen bonding between the purines and 
pyrimidines. 
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Cocrystals have been defined in various ways by various people 
12, 13, 14 
and have been 
named as “Addition Compounds” 15 (early 1900’s), “Organic Molecular Compounds” 16 
(1937), “Complexes” 17 (1960’s) or “Heteromolecular Crystals” 18 (2005) from time to 
time. Accordingly cocrystals defined in our lab states that they are “a multiple component 
crystal in which all components are solid under ambient conditions when in their pure 
form. These components or cocrystal formers coexist as a stoichiometric ratio of a target 
molecule or ion and a neutral molecular cocrystal former(s)”. 20(a) This definition 
excludes clathrates, solvates and hydrates.
 29
 As seen from the definition above, 
cocrystals contain two or more components which are held together by supramolecular 
synthons. In order to achieve that, complementary or similar functional groups in each 
molecule capable of forming supramolecular hetero or homosynthons help in the design 
of a crystal. Thus the radical in developing a cocrystals lies in the following 1) Choosing 
the target molecule 2) Finding the complementary functional groups which is capable of 
forming a hydrogen bond. 3) Methods of Preparation. This is known as the 
supramolecular synthons approach 
24, 25
 which in conjunction with analysis of the current 
structural data from the Cambridge Structural Database 
23 
helps in the discovery of 
cocrystals.  
 
1.3. Pharmaceutical Cocrystals  
Crystal form screening of APIs has become an integral part of the pharmaceutical 
industry. 
30
 This is due to the inherent nature of crystalline forms maintaining stability 
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compared to amorphous forms. Different crystal forms that can be discovered include 
salts,
 28
 hydrates,
 29
 solvates, and cocrystals. 
9
 
Pharmaceutical cocrystals, 
20, 21
 a highly studied subset of cocrystals, afford new crystal 
forms of APIs and can be defined as, “a multiple component crystal in which at least one 
component is molecular and a solid at room temperature and forms a supramolecular 
synthons with a molecular or ionic API.” 20(a) Over the years pharmaceutical cocrystals 
have been studied in the context of improving physicochemical properties including 
modifying the solubility of the parent API.
 22
 Herein reported is a study on the solubility 
of caffeine and Pentoxifylline, two molecules amenable to crystal engineering due to 
their hydrogen bond acceptors, and discuss the use of cocrystallization to tailor its 
solubility.   
Crystalline forms of API are sought as they provide stability and also helps in the 
formation of pure products. But these are also subjected to various complications arising 
from polymorphism 
26
, low aqueous solubility, amorphous nature. The existence of 
polymorphism for an API creates lots of problems arising from instability during drug 
formulation. 
Crystal engineering has created a paradigm to improve these problems. 
20(a)
 Usually when 
a new API comes into discovery, and has limited physical properties, it is converted to a 
salt form of the drug based on the ionizable functional groups in it.
 28
 Salt formation has 
been shown to be an effective tool for bettering properties without affecting the 
biological activity. But the FDA recognizes some 90 acids and 30 bases for salt formation 
and the presence of ionisable group makes it again a limited approach for neutral 
molecules.
28 
Cocrystals have come in to cross the barrier due to the large group of 
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pharmaceutically accepted compounds which can be used in its design without changing 
any properties. Pharmaceutical cocrystals opens door for multiple functional groups 
(including weakly or nonionizable) and molecules that possess a broader range of 
hydrogen bonding moieties. There are various pharmaceutical cocrystals that have been 
made in this context and examples to show how they can improve physicochemical 
properties also exist. 
22 
Other factors which make this such a versatile class of compound 
include 1) Intellectual property rights – it is considered to be a new compound, so can be 
patented. 2) It has new physical properties 3) It can be designed and does not need 
difficult steps for synthesis.  
To exemplify this, Fluoxetine Hydrochloride, also known as Prozac
®
 is a good example. 
It a popular antidepressant which is used to treat depression and bipolar disorder. The salt 
form of the drug was cocrystallized with carboxylic acids like benzoic, succinic and 
fumaric acid. On performing powder dissolution studies in water on the API and its 
cocrystals for 120 minutes the dissolution profile generated was as seen as in Figure 1.4 
(a) below. 
22(b) 
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(a)            (b)  
Figure 1.4 
22(b)
. (a) The powder dissolution profile of cocrystals of Prozac
®
 measured 
over 120 minutes shows higher solubility, lower solubility and dissociation for 
fumaric acid, benzoic acid and succinic acid cocrystals respectively.(b) Chemical 
structure of Prozac
®
. 
As seen in the profile, the cocrystal with succinic acid is seen to dissociate quickly in 
solution, and finally recrystallizing out as the API. The cocrystal with fumaric acid shows 
solubility higher than the parent API suggesting higher bioavailability and with benzoic 
acid, a decrease in the solubility is observed. 
This clearly exemplifies that cocrystals have the capacity to modify the intrinsic 
solubility of a molecule/API by either increasing or decreasing the solubility. 
To exemplify how pharmaceutical cocrystals can modify bioavailability, a good example 
would be that of Carbamezepine (CBZ), popularly known as Tegretol
®
 which has limited 
solubility. The cocrystal of CBZ with saccharin is more soluble than the pure API and its 
dehydrate form. The bioavailability when tested in vivo on dog plasma showed that the 
cocrystal had improved bioavailability as compared to the pure API. Figure 1.5(a) 
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illustrates the in vivo bioavailability studies performed on CBZ (b) depicts the crystal 
structure of the Carbamezepine·Saccharin cocrystal. 
21(a) 
 
(a)    (b)   
Figure 1.5. (a) In vivo studies conducted on Tegretol® cocrystal upon dogs showed 
that the cocrystal (red) had improved bioavailability as compared to the pure API 
(blue). (b) Crystal structure of the Carbamezepine·Saccharin cocrystal. 
Pharmaceutical cocrystals also have shown enhanced stability as for the case of 
Caffeine·Oxalic acid cocrystal as illustrated in Figure 1.6, which exhibited higher 
stability to moisture as compared to other cocrystals of caffeine and also pure caffeine 
itself. 
31 
 
Figure 1.6. The Caffeine Oxalic acid cocrystal (CSD Refcode : GANXUP) that is 
sustained by hydrogen bonding between an aromatic nitrogen of caffeine and 
carboxylic acid moieties exhibited higher stability to hydration than pure caffeine. 
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Thus as illustrated pharmaceutical cocrystals have wide range of benefits and play a 
important role in the field of pharmaceuticals and in the following chapters, 
pharmaceutical cocrystals of two API’s caffeine and Pentoxifylline are discussed along 
with solubility studies performed on them and finally analysis of melting point, crystal 
packing efficiency and solubility of cocrystal former with measured cocrystal solubility 
was also done to determine if they influenced the overall solubility. Presented herein are 
also the results of the analyses. 
 
1.4. Cambridge Structural Database 
Cambridge Structural Database (CSD) as mentioned above is an essential tool in the field 
of crystal engineering. Data collected from this software helps in understanding the 
supramolecular synthons that could be formed between functional groups. With those 
statistics it is easier to understand what complementary functional groups would be 
promising for the functional groups in a target molecule and thus the cocrystal formers 
can be selected.  
The CSD was developed in 1965 in Cambridge University by Kennard. It contains results 
of X-ray and neutron diffraction studies of organics, organometallics and complexes of 
metals. The database stores bibliographic information, crystallographic data and chemical 
connectivity information for each entry which is named as a refcode. 
23 
The CSD consists of 4 components a) ConQuest: allows searching information and 
retrieving it. b) Mercury: helps in visually looking at a structure. c) Vista: provides 
numerical analysis and d) PreQuest: helps in database creation.  
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The CSD has grown over time with a huge number of structures being deposited every 
year and as of 2011, the total number of structures in the system has gone up to 562,000. 
And thus this has become a versatile tool and a prerequisite before any crystal 
engineering experiment.  
 
1.5. Biopharmaceutics Classification System 
The Biopharmaceutics Classification System (BCS) was developed in 1995 by Amidon 
and coworkers which correlates in vitro drug dissolution and in vivo drug bioavailability. 
For orally delivered drugs, drug dissolution and permeability in the G.I tract are now 
understood as mandatory requisites. This formed the basis of the correlation developed. 
The BCS system classified drugs into 4 categories, based on aqueous solubility and 
permeability as shown in Figure 1.7 below. 
32(a)  
 
Figure 1.7. The Biopharmaceutics Classification System is based on aqueous 
solubility and permeability. 
a) Class I: Represents drugs with high permeability and high solubility. 
b) Class II: Represents drugs with high permeability and low solubility. 
c) Class III: Represents drugs with low permeability and high solubility. 
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d) Class IV: Represents drugs with low permeability and low solubility. 
Cocrystallization is a very good technique to increase the bulk solubility for drugs with 
low solubility which belongs to BCS Class II and IV. As discussed above, for example 
with CBZ which has limited solubility and cocrystallization helped to increase the 
solubility of the drug. 
The FDA guidance of BCS which was brought about in 2000, classifies a substance to be 
highly soluble when the highest dosage is soluble in 250 mL or less aqueous media over 
pH range of 1-7.5. It classifies a substance to be highly permeable when the extent of 
absorption in humans is determined to be > 90% of an administered dose based on mass-
balance or in comparison to an intravenous reference dose. 
32(b)
 
Caffeine and Pentoxifylline the two API investigated here are both BCS class I drugs and 
in this case the solubility of the API’s were decreased by cocrystallization.  
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2. CHAPTER 2: PHARMACEUTICAL COCRYSTALS OF CAFFEINE 
 
2.1. Introduction 
Caffeine (1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione) 
12 
is a natural alkaloid, methyl 
xanthine, found in various plants. It is a bitter white solid, BCS class I 
26
 API, whose 
solubility in water is 22 mg/mL at 25 ⁰C. It is the active ingredient in coffee and tea 13 
and is the most consumed central nervous system stimulant by man. Caffeine is present in 
medications for asthma, apnea in newborns, 
14
 and also some over-the-counter 
medications for headaches.  
 
 
Figure 2.1. The molecular structure of Caffeine (CSD Refcode: NIWFEE02) 
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2.2. Caffeine Metabolism and Pharmacokinetics 
Caffeine is metabolized in the liver with the help of cytochrome P450 oxidase enzymes to 
form monomethyl xanthenes, dimethyl xanthenes, monomethyl uric acids, trimethyl and 
dimethyl allantoin and also uracil derivatives. The principle dimethyl xanthenes formed 
after metabolism are paraxanthine, theophylline and theobromine which are potent 
compounds themselves. 
17(a)
 
After consumption it gets absorbed from the gastrointestinal (GI) tract rapidly and almost 
completely in humans in around 30 to 45 minutes.
 15
 The half-life of caffeine has a wide 
range (2.7-9.9.hours) primarily due to intra-subject variability. 
15, 16 
Caffeine has shown to 
be effective against various diseases including Type II diabetes 
17
 and Alzheimer’s. 19  
 
2.3. Caffeine and Alzheimer’s disease 
Alzheimer’s Disease (AD) is a neurodegenerative, incurable disease which usually 
affects people of age 65 and up. 
17(c) 
Current AD drugs can ameliorate the cognitive 
deficits to a certain degree to provide relief but not reverse the effects of AD. Deposition 
and further aggregation of the protein β-Amyloid (Aβ) in the brain is believed to be the 
cause of AD pathogenesis 
18, 19, 20(c). In lieu of that, research to prevent deposition of Aβ, 
production or removal of Aβ is being conducted. Decreasing Aβ deposition through 
inhibition of  or -secretase or promoting the non-amyloidogenic processing of the 
amyloid precursor protein (APP) through promotion of -secretase activity are other 
arenas of research for the treatment of AD. 
20(a)
 Direct removal of monomeric Aβ on the 
other hand has benefits but can also lead to erroneous consequences since it also has 
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normal cognitive functions in the brain.
 20(b)
 Caffeine has been shown to suppress Aβ 
deposition by reduction of β-secretase and -secretase, two enzymes responsible for Aβ 
production in the brain and thus revert the progression of AD pathogenesis.
 20
 
With caffeine having a rapid absorption rate and variable-to-short half-life, creation of a 
sustained dosage form of caffeine for AD patients could aid in dispensing the drug to AD 
patients over a considerable time period.  The proposal is the eventual use of caffeine 
cocrystals 
6, 7, 8 
for this purpose. The existing sustained release formulations of caffeine, 
in the form of chewing gums 
21
 or microparticulate caffeine 
22
  slow down its dissolution 
using formulation changes but do not tailor caffeine’s thermodynamic solubility. Since 
pharmaceutical cocrystals 
9, 10, 11
 have been successfully used to modify the solubility of 
many APIs 
9, 10
 and caffeine’s therapeutic potential is high, there is sufficient motivation 
to clinically develop and study alternate caffeine crystal forms.
5
  
 
2.4. Caffeine cocrystals in CSD 
Caffeine has been well studied and various crystal forms of the drug have been isolated 
and published. A more detailed analysis of the structures reported in the CSD showed 
that caffeine has been cocrystallized with carboxylic acids, polyphenols 
27, 28, 29, 30, 49
 and 
other APIs like sulfaproxiline 
58(a) 
and sulfaacetamide. 
58(b)
 Therefore, using the 
supramolecular synthon approach 
23, 24, 5 (c) 
and statistics from CSD, 
25
 cocrystal synthesis 
through crystal engineering 
1,2,3,4
 was achieved. It is shown here that caffeine can be 
cocrystallized with nutraceuticals and pharmaceutically acceptable or approved 
compounds. Solubility studies were performed on novel as well as a selected set of 
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previously reported cocrystals. Further analyses were done on the data collected to study 
the impact physicochemical properties and crystal packing had upon solubility.  
 
2.5. Experimental Section 
 
2.5.1 Synthesis of Cocrystals 
Caffeine was cocrystallized with four compounds, namely cyanuric acid, syringic acid, 
catechin hydrate and chlorogenic acid. The other cocrystal formers used in this study 
were 1-hydroxy-2-napthoic acid, quercetin, salicylic acid coumaric acid, ellagic acid, 
ferulic acid, gallic acid , ethyl gallate, caffeic acid and the cocrystals were prepared as 
previously reported in the literature 
27,28,29,30 
or prepared previously in our lab. Figure 2.2 
shows the chemical structures of caffeine and the cocrystal formers which were used in 
this study. They have all been given a 3 lettered refcode which will be used hence forth. 
All the cocrystal formers used were either Generally Regarded as Safe compounds 
(GRAS) 
47
 or included in the Every Added to Food in United States (EAFUS) 
48
 list. 
Cocrystallization with the cocrystal formers mentioned resulted in successful cocrystal 
formation of caffeine via multiple synthetic methods such as slow evaporation, solvent 
drop and neat grinding 
57
 and also slurring techniques 
28
. Single crystals suitable for X-
ray diffraction studies were also made for some cocrystals. 
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2.5.2. Caffeine·Cyanuric acid monohydrate, CAFCYA.H2O (2:1:1) 
The cocrystal was made via multiple methods (a) Solvent drop grinding: 0.038g 
(0.000195mmol) of caffeine and 0.013g (0.0001 mmol) cyanuric acid were ground with 
50 µL of ethanol for fifteen minutes in a ball mill with  two balls and it gave rise to 
CAFCYA with approximately 100% conversion. Solvent drop grinding with water and 
dimethyl formamide (DMF) also resulted in CAFCYA. (b) Dry grinding: 0.038g 
(0.000195mmol) of caffeine and 0.013g (0.0001 mmol) cyanuric acid were ground 
without any solvent and also resulted in CAFCYA with approximately 100% conversion. 
(c) Slurry: 0.38 g (0.00195 mmol) of caffeine and 0.13 g (0.001 mmol) of cyanuric acid 
was slurried at ca. 125 rpm in 4 mL of acetonitrile overnight under ambient conditions. 
The resulting solid was filtered and the filtrate was left for slow evaporation. The residual 
solid shows 100% conversion to CAFCYA. The filtrate from the slurry was left for slow 
evaporation and afforded block shaped crystals with 60% yield after seven days which 
were used for single crystals X ray diffraction.  
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Figure 2.2. The chemical structures of caffeine and cocrystal formers used in the 
study. 
2.5.3. Caffeine·Ferulic acid, CAFFER  
The cocrystal was made via the following  method in our lab (a) Slurry: 0.19 g (0.000097 
mmol) of caffeine and 0.19g of ferulic acid (0.000097 mmol) was slurried at ca. 125 rpm 
in 4 mL of methanol overnight under ambient conditions. The resulting solid was filtered 
and the filtrate was left for slow evaporation. The residual solid from the experiment gave 
100% yield of CAFFER.  
 
2.5.4. Caffeine·Syringic acid tetrahydrate ,CAFSYR.4H2O (1:1:4)  
This cocrystal was also made via multiple methods (a) Solvent drop grinding: 0.038 g 
(0.000195mmol) of caffeine and 0.040g (0.0002 mmol) of syringic acid were ground 
(ELA) 
(1HY) 
(ETG) 
(CGA) (CFA) (CAT) 
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with 50 µL of ethanol, water and DMF for fifteen minutes in a ball mill with two balls 
resulting in CAFSYR with around 100 % yield.(b) Dry grinding: 0.038 g 
(0.000195mmol) of caffeine and 0.040g (0.0002 mmol) of syringic acid was ground 
without any solvent but resulted in total conversion to CAFSYR. (c) Slurry: 0.19 g 
(0.00097 mmol) of caffeine and 0.20g of syringic acid (0.001 mmol) was slurried at ca. 
125 rpm in 5 mL of water overnight, under ambient conditions. The resulting solid was 
filtered and the filtrate was left for slow evaporation. The residual solid gave 100% 
conversion to CAFSYR. The filtrate from the slurry was left for slow evaporation and 
gave rise to needle shaped crystals with 85 % yield after 10 days which was used for 
single crystal analysis.  
 
2.5.5. Caffeine·Ethyl gallate dihydrate, CAFETG.2H2O (1:1:2) 
This cocrystal was also made via the slurring technique in our lab (a) Slurry: 0.19 g 
(0.00097 mmol) of caffeine and 0.20g of ethyl gallate (0.001 mmol) was slurried at ca. 
125 rpm 3 mL of a 50:50 mixture of ethanol: water, overnight under ambient conditions. 
The resulting solid was filtered and the filtrate was left for slow evaporation. The solid 
resulted in total conversion to CAFETG.  
 
2.5.6. Caffeine·Caffeic acid, CAFCFA  
This cocrystal was prepared via the following method in our lab. (a) Slurry: 0.19 g 
(0.00097 mmol) of caffeine and 0.18 g of caffeic acid (0.001 mmol) was slurried at ca. 
   
25 
 
125 rpm in 5 mL of water overnight, under ambient conditions. The resulting solid was 
filtered and the filtrate was left for slow evaporation. The residual solid gave 100% 
conversion to CAFCFA.  
 
2.5.7. Caffeine·Chlorogenic acid, CAFCGA   
0.38 g (0.00097 mmol) of caffeine and 0.354 g of chlorogenic acid (0.001 mmol) was 
slurried at ca. 125 rpm in l mL of water overnight, under ambient conditions. The 
resulting solid was filtered and the filtrate was left for slow evaporation. The residual 
solid showed 100% conversion to CAFCGA. Suitable single crystals for X-ray diffraction 
studies could not be grown for this cocrystal.  
 
2.5.8. Caffeine·Quercetin methanol solvate, CAFQUE.MeOH (1:1:1)  
This cocrystal was prepared by in our lab by taking 0.19 g (0.00097 mmol) of caffeine 
and 0.34 g (0.001 mmol) of quercetin was slurried at ca. 125 rpm 5 mL of methanol, 
overnight under ambient conditions. The resulting solid was filtered and the filtrate was 
left for slow evaporation. The solid resulted in 100% cocrystal CAFQUE. 
 
2.5.9. Caffeine·Salicylic acid, CAFSAL (1:1) 
The cocrystal was prepared as outlined in the paper by Bucar et al. 
27  
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2.5.10. Caffeine·1-hydroxy-2-napthoic acid, CAF1HY (1:1)  
The cocrystal was prepared as outlined in the paper by Bucar et al. 
28 
 
2.5.11. Caffeine·Ellagic acid Monohydrate, CAFELA.H2O (1:1:1) 
The cocrystal was prepared as outlined in the paper by Clarke et al. 
29  
  
2.5.12. Caffeine·Gallic acid Hemihydrate, CAFGAL.0.5H2O (1:1:0.5)  
The cocrystal was prepared as outlined in the paper by Clarke et al. 
29
  
 
2.5.13. Caffeine·Coumaric acid, CAFCOU (2:1)  
The cocrystal was prepared as outlined in the paper by Schultheiss et al. 
30
  
 
2.5.14. Caffeine·Catechin Hydrate, CAFCAT  
This cocrystal was prepared by in our lab by taking 0.19 g (0.00097 mmol) of caffeine 
and 0.29 g (0.001 mmol) of catechin hydrate was slurried at ca. 125 rpm five ml of ethyl 
acetate, overnight under ambient conditions. The resulting solid was filtered and the 
filtrate was left for slow evaporation. The solid resulted in 100% cocrystal CAFCAT. 
Single crystals could not be grown for this cocrystal but the cell parameters and space 
group were retrieved. 
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2.5.15. Dissolution studies on cocrystals 
Powder dissolution studies were performed on all cocrystals and pure caffeine. The study 
was performed in deionized water at room temperature. All the crystal forms were sieved 
to get consistent particle sizes between 53 -75µm as the dissolution rate is affected by 
particle size. Supersaturated slurries were stirred with magnetic sir bars at a rate of 125 
rpm. Dissolution rate was determined by drawing fixed aliquots with a syringe and 
filtering through 0.45µm filters after 5, 10, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 
240, and 2400 minutes. The solutions were analyzed to determine the concentration of 
caffeine using HPLC with UV/Vis detection. The experiment was done in triplicate to 
allow for statistical analysis. The leftover solid was characterized at the end of the study 
identify the solid phase post dissolution.
38
  
 
2.6. Results  And Discussion 
 
2.6.1. Cocrystals of Caffeine  
Caffeine has been a molecule of choice in the field of crystal engineering owing to its 
capacity to readily form hydrogen bonds with complementary functional groups such as 
carboxylic acids, polyphenols and amides and these types supramolecular heterosynthon 
formation are exemplified by structures deposited in the CSD.
25 
A survey of the CSD 
(version 5.32, May 2011 update) was carried out using ConQuest (version 1.13) and the 
search was limited to organic molecules with determined 3D coordinates determined and 
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R ≤ 0.075. This survey revealed 44 entries of caffeine including solvates. A caffeine 
molecule has three hydrogen bond acceptors including an aromatic nitrogen in the 
imidazole ring (Narom) and two carbonyl groups. Carboxylic acids, alcohols, phenols and 
amides have hydrogen bond donors which readily participate in hydrogen bonding and 
the CSD survey mentioned above contained these types of hydrogen bond donors 
interacting with caffeine. On performing a CSD analysis with these acceptor centers in an 
earlier study, it has been seen that the Narom···COOH supramolecular heterosynthon has a 
98 % occurrence, the Narom···OH has a 78% occurrence incidence and Narom···CONH2  has 
a 33%  incidence of occurrence; 
5(c)
  in the absence of competing functional group and 
homosynthons. A similar statistical analysis conducted for the carbonyl group determined 
that the carbonyl group specific to the structure has lower incidences of bonding with 
carboxylic acids, alcohols, phenols and amides. 
In the study, caffeine cocrystals with 1-hydroxy-2-napthoic acid (KIGKIV) 
28
, salicylic 
acid (XOBCAT) 
27
, coumaric acid 
30   
have been included from the literature. Cocrystals 
of caffeine with gallic acid, ellagic acid and quercetin were made in our lab and published 
earlier 
29
. It has been remade and used for the purpose of this study.  
The statistics concretely shows that the radical for using the three complementary groups 
are promising and logical choices for cocrystallization.  
The cocrystal formers that were targeted for the study are illustrated in Table 2.1, 2.2 and 
2.3 below.  
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Table 2.1. Cocrystal formers- carboxylic acids 
Name  M.W  M.P  pka   LD 
50(mg/kg) 
Solubility  
(mg/ml)  
Glycolic 
acid  
76.05  75-80  3.82  1950, oral 
rat  
soluble  
Salicylic 
acid  
138  158  2.97 
,13.4  
891 , oral 
rat  
2  
Benzoic 
acid  
122.12  122.4  4.21  oral, rat 
1700  
3.4  
 
Table 2.2. Cocrystal formers – polyphenols and flavanoids 
Name  pka   LD 
50(mg/kg) 
Solubility  
(mg/ml)  
Caffeic acid 4.4 721 0.7 
Gallic acid  4.5,10  5000  11  
Catechin 
Hydrate 
7.8 3890 1.6 
Syringic acid  4.33, 7.5  2000  0.57  
Chlorogenic acid  3.34  100  25  
Coumaric acid  4.4,9.35  2850  0.8  
Ferulic acid  4.8,9.4  3890  0.7  
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Table 2.3. Cocrystal formers- amides 
Name M.W  pka  Solubility 
(mg/ml)  
 LD 
50(mg/kg)  
M.P  
Cyanuric 
acid 
129.07 6.9  2.7  7700  Rat 
oral.  
320-360  
Iso 
nicotinamide  
122.12  3.67  191.7  78 rat oral  155-158     
Salicylamide  137.136  8.32  soluble  980 , rat oral  140            
 
 
2.6.2. Crystal Structure Discussion:  Caffeine Cyanuric acid monohydrate 2:1:1 
Caffeine.Cyanuric acid, CAFCYA crystallizes in the space group P21/n. The asymmetric 
unit contains two caffeine molecules, one cyanuric acid and one water molecule. Figure 
2.3 demonstrates hydrogen bonding between the molecules which are arranged in tapes, 
in one sheet. Each cyanuric acid molecule acts as a donor to two caffeine molecules 
through interaction with the imidazole nitrogens, N···N. 2.913(5) Å, 2.953(5) Å, and one 
water molecule with an N···O distance of 2.712(4) Å. The water molecule also hydrogen 
bonds to a carbonyl of another cyanuric acid molecule with an O···O distance of 2.753(4) 
Å thereby connecting the cyanuric acid molecules in a chain. The water molecule which 
connects the cyanuric acids, is also seen to participate in hydrogen bonding with one 
carbonyl (adjacent to the imidazole ring) of caffeine in the sheet below it with an O···O 
distance of 2.791(5) Å as depicted in Figure 2.4. This finally results in the bilayer sheets 
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supported by π-π interactions, depicted for clarity in two colors and designated as 
AABBAABB in Figure 2.5. Data were collected on single crystals of CAFCYA and 
CAFSYR on a Bruker-AXS SMART APEX 2 CCD diffractometer with 
monochromatized Cu Kα radiation (λ = 1.54178 Å). The diffractometer was connected to 
a KRYO-FLEX low temperature device. Data for CAFCYA was collected at 105 K and 
CAFSYR at 293 K. Indexing was performed using SMART v5.625 
31(a)
 or using APEX 
2008v1-0. 
31(b)
 Frames were integrated with SaintPlus 7.51 
32
 
 
software package. 
Absorption corrections were performed by multi-scan method implemented in SADABS. 
33
 The structures were solved using SHELXS-97 and refined using SHELXL-97 (Matrix 
Non-Linear Least- Squares) contained in SHELXTL v6.10 
34
 and WinGX v1.70.01
35.36, 37
 
program packages. 
A search for cyanuric acid in the CSD revealed 12 cocrystals of the compound. Out of 
them, in cyanuric·urea (PANVUV), the NH of cyanuric acid forms a supramolecular 
heterosynthon with the amide group of urea, cyanuric acid·phenazine (YIZXID) shows 
cyanuric acid molecules forming dimers with each other and the phenazine molecules 
stacked by π-π interactions. BADCUR, cocrystal between cyanuric acid and 8-bromo 9-
ethylene adenine is a monohydrate where water bridges the compounds together in the 
lattice. Other than these, all the other 9 cocrystals reported, HADCUT, ZIHEE, 
MOPYAR, VEDFAM, YIZXAH, VEXQUE and VEXQUK show supramolecular 
heterosynthon between aromatic nitrogen and NH of cyanuric acid. 
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Figure 2.3. Hydrogen bonding observed in CAFCYA.H20 reveals that the aromatic 
nitrogen of caffeine forms a supramolecular heterosynthon with the NH group on 
cyanuric acid molecules. Cyanuric acid molecules are connected by water molecule 
thereby affording a tape like structure. 
 
 
Figure 2.4. Stacking of CAFCYA.H20 sheets viewed along b-axis. Water molecules 
bridge the layers. 
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Figure 2.5.  Bilayer sheets of CAFCYA.H20 viewed along the c-axis. 
 
2.6.3. Caffeine ·Syringic acid tetrahydrate 1:1:4  
The cocrystal caffeine·syringic acid, CAFSYR  crystallizes in Fdd2. Each assymmetric 
unit contains one caffeine molecule, one syringic acid molecule and four water 
molecules. The interactions between the molecules are shown in Figure 2.6. The carbonyl 
moiety in the carboxylic acid in syringic acid  engages in hydrogen bonding with one 
water molecule at an O···O distance of 2.8(4) Å. This water molecule in turn engages in 
hydrogen bonding with two additional water molecules, to form an O···O hydrogen 
bonded chain, O···O, 2.7(5) Å, 2.8(6) Å. The hydroxyl moeity of the carboxylic acid on 
syringic acid hydrogen bonds to a third water molecule,via O···O interactions at distances 
of  2.6 (4) Å which is in turn hydrogen bonds to the aromatic nitrogen of caffeine on one 
side through an O···N interaction ,O···N at a distance of 2.8(5) Å and another water 
molecule above, OH···O at a distance of 2.9(5) Å. This water engages in hydrogen bond 
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with the carbonyl group adjacent to the imidazole ring of caffeine , O···O at a distance of  
2.6(5) Å. The hydroxy group on syringic acid and one methoxy group bonds with the 
fourth water molecule O···O at a distance of 2.8 (4) Å. This water molecule now is found 
to bond with the first water molecule and another syringic acid molecule to from a 
terameric structure as shown in Figure 2.7. Intramolecular hydrogn bonding is also seen 
to occur between the hydroxyl group of syingic acid and methoxy group, O···O at a 
distance of 2.7 (4) Å. The water molecule which points downward forms the bridge,O···O 
at a distance of 2.8(5) Å. 
A CSD analysis of syringic acid shows that there are no reported crystal forms of this 
compound, thereby making caffeine·syringic acid the first cocrystal ever reported. 
Figure 2.6. Hydrogen bonding in CAFSYR.4H2O reveal that carboxylic acid 
moieties and aromatic nitrogen atoms of caffeine form a heterosynthon with water.  
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 Figure 2.7. The tetrameric structure formed between water molecules and syringic 
acid in CAFSYR.4H2O.  
 
2.6.4. Caffeine Chlorgenic acid, Caffeine Catechin Hydrate   
These cocrystals were prepared via various methods in a 1:1 ratio as mentioned in the 
experimental section and characterized via PXRD, TGA, DSC and FT-IR. Efforts to 
prepare single crystals however did not yield any results as of yet. For caffeine·catechin 
hydrate though the crystal structure was not resolved but the cocrystal was indexed to 
P212121. 
A search of chlorogenic acid in the CSD yields 2 salt 
39
 entries with caffeine, no 
cocrystals are reported. In case of catechin hydrate, only the crystal structure of catechin 
hydrate (LUXWOR) is reported, no cocrystals of catechin hydrate are reported making 
this one with caffeine the first reported cocrystal. 
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2.6.5. Dissolution and Solubility Studies 
Powder dissolution studies were done on I-XII in aqueous media to determine the 
dissolution profile for each cocrystal. Caffeine’s dissolution profile was also determined 
over twenty-four hours to show the change of caffeine to caffeine monohydrate. For 
purposes of clarity, the time point for the 24
th
 hour reading was changed to 480 minutes. 
This is made evident after the solubility of the anhydrous material reduces to 22.09 
mg/mL which is in agreement with literature reported solubility of caffeine.
50 
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Figure 2.8.  Dissolution profiles in water for caffeine and CAFCYA.H2O, 
CAFQUE.MeOH and CAFSAL. 
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Figure 2.9. Dissolution profiles in water for CAFFER, CAFETG.2 H2O, CAFCOU, 
CAF1HY and CAFELA.H20. 
The dissolution profiles have been divided into 2 figures for clarity. Figure 2.8 shows the 
kinetic solubility profiles of caffeine and caffeine cocrystals CAFCYA.H2O, 
CAFQUE.MeOH and CAFSAL with solubility in the range of 3-22 mg/mL. Figure 2.9, 
shows the kinetic solubility profiles for cocrystals CAFFER, CAFETG.2H2O, 
CAFCOU, CAF1HY and CAFELA.0.5H2O with solubility ranging between 0.1- 2.9 
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mg/mL.  For cocrystals CAFCGA, CAFGAL.0.5H2O, CAFSYR.4H2O and CAFCGA 
the profiles generated are similar to those shown above.  
From Noyes-Whitney’s 40 initial experiments on dissolution, thermodynamic solubility of 
a crystal form is a fixed property upon which the rate of dissolution is dependant. With 
the change in thermodynamic solubility of the caffeine in the cocrystals, the dissolution 
rate is also modified and the smooth curves exemplify the constant dissolution rates 
achieved for the cocrystals. A comparative graph showing the thermodynamic solubility 
of each cocrystal and caffeine measured over twenty-four hours has been shown in the 
Figure 2.10. The figure demonstrates the wide range of solubility that has been achieved 
by different cocrystals. 
 
Figure 2.10. A comparison of the thermodynamic solubility of caffeine and its 
cocrystals. 
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From the dissolution study it can be seen that CAFCYA.H2O showed maximum 
concentration of ca 12.6 mg /mL till 3 hours and then lowers down to ca 10 mg/mL over 
24 hours. CAFQUE.MeOH shows maximum concentration of ca 8.55 mg/ mL by the 
end of 24 hours. CAFSAL’s dissolution profile shows a smooth plateau after reaching a 
maximum concentration of ca 3.5 mg/ mL. CAFETG.2H2O, CAF1HY, CAFELA.H2O  
and CAFCOU also show smooth plateau like profiles with maximum concentration of ca 
0.5 mg/ mL ca 0.23 mg/ mL, and ca 0.08 mg/ mL, and ca 1.1 mg/ mL respectively.  On 
the other hand CAFER shows a profile which shows maximum concentration at ca 3.3 
mg/ mL and then reducing to ca 2.85 mg/ mL over 24 hours. The profile suggests that the 
crystal form shows signs of forming a hydrate after dissolving in water, which is less 
soluble than the anhydrous form 
41, 42 
but has the same powder pattern as seen before the 
study possibly implying formation of an isostructural hydrate of the crystal form.  
The thermodynamic solubility data of CAFSYR.4H2O was found to be ca 1.17 mg/ mL 
The maximum concentrations of CAFCFA, CAFCGA and CAFGAL.0.5H2O were 
recorded as follows ca. 0.6 mg/mL, 11.9 mg/mL and 5.7 mg/mL respectively. This 
solubility data clearly indicates that a lower  solubility crystal form for caffeine can be 
achieved at different magnitudes depending on the cocrystal former employed which are 
thermodynamically stable over 8 hours. The PXRD and DSC’s of the residual solids were 
done after the study at the end of twenty four hours and it was found that the all the 
cocrystals were stable till that time period.  
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2.6.6. Caffeine as a drug 
Amidon’s 43 solubility studies tell us that for a drug to be freely soluble and permeable in 
the body the ideal solubility of the drug should be greater than or equal to 1 mg/mL. As 
seen from the data CAFCYA.H2O, CAFER, CAFSYR.4H2O, CAFCGA, 
CAFQUE.MeOH, CAFSAL, CAFGAL.0.5H2O and CAFCOU achieve solubility 
above 1 mg/mL showcasing their suitability as drugs. As mentioned before, a slow 
release, sustained dosage form of caffeine is desirable for AD. The solubility data of 
these crystal forms exhibit a wide range of solubility and showcases their possible utility 
for a sustained dosage form of caffeine. Thus crystal engineering affords a wide range of 
solubility for an API through cocrystallization and this study clearly shows that the above 
mentioned cocrystals of caffeine can be used as suitable alternate forms for oral delivery 
as.  
 
2.6.7. Correlation between Solubility and Melting Point 
For thermodynamically stable cocrystals this correlation is important. It could help to 
know if solubility of an API could be tailored on the basis of melting point.  Various 
studies have been done but this relation still remains elusive. 
10(b)
 Attempts to correlate 
the log of the solubility and the onset of the melting point of the cocrystal for this dataset 
were unsuccessful most probably due to the variability in the cocrystal formers used. 
(Shown in Figure 2.11 below). This result is consistent with Bak et al’s 9(d) recent data.  
Table 2.4 below shows the comparison of melting points of cocrystal and cocrystal 
former. 
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Figure 2.11. Solubility of cocrystals shows no relationship with melting point 
probably due to the variability of coformers used. 
Table 2.4. Melting points of the cocrystal formers and the cocrystals 
COCRYSTAL /COMPOUND M.P. of compound/ cocrystal 
(⁰ C) 
M.P of CCF (⁰ C) 
CAF 238   
CAFCYA.H2O 228   360(decom) 
CAFFER 147 168 
CAFSYR.4H2O 180 205 
CAFETG.2H2O 145 149 
CAFCFA 200 211 
CAFCGA 131 210 
CAFQUE.MeOH 244 310 
CAFSAL 147 158 
CAF1HY 190 195 
CAFELA.H2O 304  360 (decom) 
CAFGAL.0.5H2O 244 268 
CAFCOU 178 214 
(* Melting points were taken from scifinder.org) 
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On trying to correlate these two parameters between specific classes of compounds, some 
correlations were observed. On comparing melting point onsets of cocrystals of caffeine 
with cinnamic and hydroxy cinnamic acids 
51
 (ferulic acid, caffeic acid, coumaric acid 
and chlorogenic acid) a correlation of 85% was observed, as shown in Figure 2.12. It was 
seen that with increase in melting point of the cocrystal, a decrease in solubility occurred. 
 
 
Figure 2.12. Solubility of cocrystals shows a high correlation with melting point 
within the specific group of cinnamic and hydroxycinnamic acids. 
This study shows that compounds belonging to individual classes do show that solubility 
and melting point are related in some ways. To come to a consensus of how different 
classes of compounds might vary in solubility and if melting point is a versatile cocrystal 
design parameter, more systematic studies like need to be done amongst various classes 
of compounds for multicomponent cocrystals. 
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2.6.8. Correlation between solubility of cocrystal former to solubility of cocrystal 
The collected data shows that there has been a decrease in the solubility of caffeine 
through cocrystallization as compared to the original API and in this context the above 
parameters were correlated to determine any relationship between them as shown in 
Figure 2.13 similar to analysis conducted by Nair et al where it was shown that with the 
increase in the solubility of the cocrystal former there is an increase in the solubility of 
cocrystal. 
44 
It has been seen that in this case all the cocrystal formers are of solubility 
lower than and comparable to caffeine, the cocrystals are thermodynamically stable over 
24 hours, and there is a general trend of decrease in caffeine solubility in the cocrystals. 
But there is no correlation observed that could help in prediction of solubility. 
 
 
Figure 2.13. On correlating cocrystal former solubility and cocrystal solubility no 
correlation other than the general decrease is observed in cocrystal solubility. 
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2.6.9. Correlation between solubility and crystal structure  
All the cocrystals were classified according to their solubility following Amidon’s 43 
solubility classification. No trends could be seen when the study encompassed cocrystal 
formers of wide range of solubility as shown in Table 2.5. On then trying to see if the 
crystal structures themselves had an impact upon solubility. Amongst all the cocrystals 
CAFSAL, CAF1HY and CAFCOU are anhydrous structures, whereas others are 
hydrates or solvates. In lieu of that there is no structure specific property observed that 
could be distinguishing between the structures.  Considering that Narom of caffeine is the 
principle hydrogen bond acceptor with phenols and carboxylic acids as compared to the 
other bond acceptors in caffeine, it has been seen that the principle synthons noticed 
involving the aromatic nitrogen do not render any conclusive result or relationship.  
Table 2.5. Solubility classification of cocrystal formers according to Amidon 
43
 
Practically 
insoluble(<0.1mg/mL) 
CCF  
Very slightly 
soluble(0.1-1 
mg/mL) CCF  
Slightly soluble 
(1-10mg/mL) 
CCF  
Sparingly 
soluble(10-
33mg/mL) CCF  
QUERCETIN  COUMARIC 
ACID  
CYANURIC 
ACID  
GALLIC ACID  
ELLAGIC ACID  FERULIC ACID  SALICYLIC 
ACID  
CHLOROGENIC 
ACID  
 1-HYDROXY- 2 
NAPTHOIC 
ACID  
ETHYL 
GALLATE  
 
 CAFFEIC ACID  SYRINGIC 
ACID  
 
 
 
 
   
46 
 
2.6.10. Relationship between Solubility and Crystal packing efficiency 
Polymorphic compounds are known to have different crystal packing and that is one 
factor that contributes to different physicochemical properties between them.
 45
 Since it is 
known that molecules arrange themselves in different ways, crystal packing efficiency is 
an important calculable parameter that could showcase and shed some light on the 
observed solubility. With new forms showing different physicochemical properties, it is 
envisaged that crystal packing plays a critical role. Crystal packing efficiency was 
calculated for the cocrystals of caffeine (using the software Platon 
53
) and correlated as a 
function of solubility. To define the regularities of formation of molecular crystals, 
Kitaigorodskii established the principle of close packing which is based on the 
understanding of the tendency of molecules to fill available space in the most efficient 
way with the greatest number of energetically favorable intermolecular van der Waals 
contacts.
 46
 Crystal packing efficiency helps to calculate the efficiency of the molecules to 
pack closely. For organic molecules, efficiency is typically found to be in the range of 
65%-77%. The following, Table 2.6, depicts solubility of the cocrystal/compound with 
single crystal data and its corresponding packing efficiency. Caffeine monohydrate’s 54 
packing efficiency was determined here as it is the thermodynamically stable form during 
dissolution and was thus a more appropriate compound to compare to than anhydrous 
caffeine.  
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Table 2.6.  Crystal packing efficiency and solubility of caffeine monohydrate and 
crystal forms 
 Compound/Cocrystal 
Crystal packing 
efficiency(%) Solubility(mg/mL) 
Caffeine Monohydrate 65 22.09 
CAFCYA.H2O 75 10.01 
CAFSYR.4H2O 72 1.17 
CAFETG.2H2O 70.1 0.56 
CAFQUE.MeOH 72.9 8.55 
CAFSAL 73.8 3.5 
CAF1HY 71.8 0.23 
CAFELA.H2O 75.6 0.08 
CAFGAL.0.5H2O 74.9  5.7 
 
As shown in Figure 2.14 below, there is a 41% correlation between crystal packing 
efficiency and solubility, which indeed provides the impression that crystal packing 
might play a role in the solubility of crystal forms. For example, caffeine monohydrate 
has the highest solubility and the lowest packing efficiency whereas CAFELA (X) has 
the highest packing efficiency and the lowest solubility, thus the crystal packing can have 
a vital effect upon the solubility of the crystal form. 
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Figure 2.14.  On correlating crystal packing efficiency with solubility shows that 
highest packing efficiency is achieved by lowest solubility cocrystal and vice versa. 
 
2.6.11. Determination of solubility of cocrystal former from solubility of cocrystal 
It is definite that with change in solubility of API or principle cocrystal former in the 
cocrystal , there is also a change in the solubility of the other cocrystal former. In our 
cocrystals, the cocrystal formers are mostly nutraceuticals. Nutraceuticals 
55
 are a class of 
compounds which benefits human health and is defined as a  medicinal or nutritional 
component that includes a food, plant or naturally occurring material, which may have 
been purified or concentrated, and that is used for the improvement of health by 
preventing or treating a disease 
55(c)
. They can be used as pharmaceuticals, dietary 
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supplements etc. Dietary polyphenols are also considered nutraceuticals. They are the 
principle antioxidants in food. 
52,55(c).
 
The cocrystal formers cyanuric acid and 1-hydroxy-2-napthoic acid too are safe 
compounds. And as mentioned before, changes occur in both the formers during 
cocrystallization thereby helping in tailoring the solubility of both of the components in 
the cocrystal.  
The experimental solubility of both caffeine and the cocrystal former’s were compared to 
the measured solubility of caffeine and literature values for the other cocrystal formers. 
The results are shown in the Table 2.7 below.  
Notably, amongst all the cocrystal formers the two least soluble compounds, quercetin 
59 
and ellagic acid 
60 
have shown massive increase in solubility, approximately 5000 and 12-
fold, respectively.  
 
Table 2.7. Solubility modification (increase or decrease) of caffeine and other 
cocrystal former in caffeine crystal forms 
Cocrystal  
 
With respect  to 
CCF(Increase(inc) 
/Decrease(dec)  
With  respect to caffeine 
(decrease)  
CAFCYA.H2O 1.2 fold(inc)  -2 fold 
CAFFER  -8 fold  
CAFSYR.4H2O -0.209 fold(dec)  -19 fold  
CAFETG.2H2O -0.1428 fold(dec)  -39 fold 
CAFQUE.MeOH 5354 fold(inc)  -3 fold 
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CAFCFE  -33 fold 
CAFCGA  -2 fold 
CAFSAL 1.24 fold(inc)  -6 fold  
CAF1HY -0.45 fold(dec)  -96 fold 
CAFELA.H2O 12.8 fold(inc)  -278 fold 
CAFGAL.0.5H2O -0.45 fold(dec)  -4  fold 
CAFCOU -0.844 fold(dec)  -20 fold  
 
Thereby , formation of cocrystals of API or compounds with the other component or 
cocrystal formers can be chosen in such a way during co crystallization such that the 
solubility of both the components altered can be beneficial to us.  
 
 
2.7. Conclusion 
 
In summary, pharmaceutical cocrystals posses the ability to tailor the aqueous solubility 
of an API.  This statement is exemplified by the case study presented here where the 
cocrystals of caffeine lowered the solubility of caffeine, allowing for the potential of a 
slow release drug for the treatment of AD. 12 cocrystals of caffeine were studied and 
their solubility in water analyzed.  
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All the crystal forms were tested to determine the aqueous solubility and dissolution 
profile. All of them were found to be thermodynamically stable till after twenty-four 
hours. The dissolution profiles showed that CAFELA.H2O had achieved the lowest 
concentration of 0.08 mg/mL. On looking at the profiles some have achieved  solubilities 
above 1 mg/mL showcasing their suitability as a drug for AD which will be a slow 
release form of  caffeine as visible from the smooth plateau’s of their dissolution profiles. 
The effects of melting point, solubility of cocrystal former and crystal packing efficiency 
upon solubility were also studied. It was seen that, in general, melting point could not be 
correlated as a function of solubility probably due to the variability in cocrystal formers, 
but when correlated amongst specific class of compounds like the hydroxycinnamic 
acids, high correlations amongst these two parameters could be seen, suggesting that 
amongst specific classes even multicomponent cocrystals can show this correlation and 
can be used to tailor solubility based on the melting point that one would want. 
Further studies were performed considering solubility as a function of crystal packing 
efficiency. Crystal packing is a important parameter for crystalline compounds. It was 
found from the data, that a 41% correlation occurs between solubility and packing 
efficiency; with the highest packing efficiency having the lowest solubility and vice 
versa. Caffeine monohydrate with the highest solubility had the lowest packing efficiency 
and all the cocrystals of varying solubility showed higher packing efficiency. This shows 
that this property could be important and will help in future understanding of cocrystal 
solubility.  
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Influence of supramolecular synthons could not be established as a function of solubility. 
In case of relation between the cocrystal former and cocrystal solubility, a general trend 
was observed, where coformers used herein with solubility lower than caffeine , an 
overall  decrease in the solubility of the pure API occurred , but no specific relationship 
between them could  be established showing that predicting solubility is not a possibility.  
It was determined that solubility of the cocrystal formers alters the solubility of the target 
API or compound. More specifically, it was shown here that some cocrystal formers can 
have a huge impact upon solubility such as Quercetin. Quercetin is an insoluble flavonoid 
has shown an approx. 5000 fold increase in solubility as a cocrystal with caffeine. Ellagic 
acid another insoluble flavonoid showed a 12 fold increase in its solubility.  
Caffeine’s solubility was thus successfully lowered through cocrystallization with 
nutraceutical or pharmaceutically acceptable compounds. Predictability of the resultant 
solubility through melting point or coformer solubility correlation was not successful but 
it was shown that cocrystals with packing efficiencies greater than caffeine hydrate 
maintained  lower aqueous solubility’s over the time studied.  
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3. CHAPTER 3: PHARMACEUTICAL COCRYSTALS OF PENTOXIFYLLINE 
 
3.1. Introduction  
Pentoxifylline popularly known as TRENTAL
®
, a drug sold by Aventis, is a 
methylxanthine derivative drug and belongs to the same class like caffeine, theophylline 
and theobromine. It is available as tablet, film-coated tablet and sugar-coated tablet 
formulations containing dosage of 100, 200 and 400 mg respectively. It is also 
administered intravenously.
1 
It is a white, crystalline powder which has a bitter taste with slight odor, with a reported 
solubility of 77mg/mL at 25⁰C in water and pka is reported as 0.28. 2 
Pentoxifylline is essentially used for treatment of intermittent claudication, ischemia of 
heart, Reynolds syndrome, diabetes, cerebrovascular diseases and also uremia. 
3, 4, 5 
All 
these disorders have red blood cell deformity which is improved by the API by increasing 
membrane ATP. 
3
 Pentoxifylline also blocks platelet aggregation, stimulates fibrinolysis 
and decreases plasma fibrinolysis levels, thereby showing its effects as a hemorrheologic 
drug. 
3
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Figure 3.1. The molecular structure of Pentoxifylline (CSD Refcode : JAKGEH). 
3.2. Pharmacokinetics and Metabolism 
Pentoxifylline is absorbed from the GI tract readily but undergoes extensive first pass 
metabolism .
2
 On giving the drug via I.V. route the half life of the drug is 1.63 ± 0.8 
hours. In case of oral delivery of the drug, the tmax is around 0.29-0.41 hours with the half 
life ranging in between 0.39-0.84 hours.
2
 Since it undergoes metabolism, the 
bioavailability of the sustained release form of the drug is around 20% and 30% for 
capsules. 
5 
Pentoxifylline gets metabolized in the liver and red blood cells and forms 7 metabolites. 
5 
Excretion of the metabolites occurs via urine. 
2 
 
3.3. Pentoxifylline and Autism 
Pentoxifylline is a phosphodiesterase inhibitor and has been contraindicated for use in 
autism. 
6 
Autism is a disorder 
7
 in which there are developmental problems in the central 
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nervous system and affects children and the signs are visible from the age of 2. Though 
there are pharmacological therapies targeting symptoms and behavioral therapies, no 
specific treatment for the disease is available yet. Antipsychotic drugs like Risperidone 
and Haloperidol are mostly used and Risperidone is shown to be well tolerated and 
efficacious in treating behavioral symptoms in patients but not cure the disease. It has 
been found that autism is linked not only to hemorrheologic property but also has 
inhibitory effects on tumor necrosis factor-α which is a vital cytokine in vivo and in vitro 
and is found to be in higher levels in autistic patients than in controls. TNF- α (Tumor 
Necrosis factor) affects the neuroendocrine system, causes death of oligodendrocites and 
demyelation and is suggested to play a vital role in neurologic disorders like multiple 
sclerosis AIDS. Autistic patients have been treated from time to time with Pentoxifylline 
and these studies have shown promising results. Pentoxifylline was also studied in a 
double blinded placebo test with Risperidone and the results showed that with it, the 
symptoms, both immunological and behavioral were reduced within 10 weeks as 
compared to that of the placebo. 
7 
Though there are sustained release forms of the drug 
8
 and various formulations are made 
for sustained dosage of the highly soluble drug, none of them cater to reducing the 
solubility of the drug such that the dissolution rate is reduced giving rise to a longer half 
life of the drug. Thus, with a drug with such great potential and pharmaceutical cocrystals 
actively helping in tailoring solubility of an API, cocrystals of the API were made which 
could be used clinically in the future.  
Using the supramolecular synthon approach 
9, 10  
and statistics from CSD, 
20
 cocrystal 
synthesis through crystal engineering was achieved. It is shown here that Pentoxifylline 
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can be cocrystallized with nutraceuticals 
11
 and pharmaceutically acceptable or approved 
compounds. Solubility studies were performed on the novel set of cocrystals. Further 
analyses were done on the data collected to study the impact physicochemical properties 
and crystal packing had upon solubility.  
 
3.4 Experimental Section 
 
3.4.1. Cocrystal synthesis 
Pentoxifylline was cocrystallized 
17, 18 
 with benzoic acid, salicylic acid, 1- hydroxy-2-
napthoic acid, caffeic acid, coumaric acid, gallic acid, salicylamide and catechin hydrate. 
Chemical structures of all the compounds along with the 3 letter refcodes are illustrated 
in Figure 3.2. These refcodes will be used to designate cocrystals henceforth. The 
cocrystal formers used in this study are broadly carboxylic acids, amides, polyphenols 
and flavonoids. Some of the cocrystal formers used have health benefits associated with 
them. 
Caffeic acid, coumaric acid, gallic acid, salicylic acid and catechin hydrate are 
nutraceutical compounds with antioxidant properties. 
11, 12, 13 
Salicylamide, a non 
prescription drug is used as an over the counter pill with other API’s like caffeine and 
aspirin. It has anti inflammatory, mild analgesic and antipyretic properties. Benzoic acid 
and 1-hydroxy-2-napthoic acid are GRAS (Generally regarded as Safe) listed carboxylic 
acids. 
14
 Cocrystallization with the above mentioned conformers resulted in successful 
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cocrystal formation with Pentoxifylline via multiple methods such as slow evaporation, 
solvent drop grinding 
15
 and also slurring 
16
 techniques.  Single crystals suitable for X ray 
diffraction studies were also made for most of the cocrystals. 
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Figure 3.2. The chemical structures of Pentoxifylline and cocrystal formers used in 
the study. 
3.4.2. Pentoxifylline·Benzoic acid, PENBEN (1:1)  
This cocrystal was made via multiple methods (a) Solvent drop grinding: 0.028 g (0.0001 
mmol) of Pentoxifylline and 0.012g (0.0001 mmol) of benzoic acid were ground with 
50µL of ethanol for fifteen minutes in a ball mill with two balls resulting in PENBEN 
(PEN) (GAL) (SAL) 
(BEN) (CFA) 
(1HY) 
(COU) (CAT) (SLC) 
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with 100 % yield. Solvent drop grinding with water and DMF also resulted in PENBEN. 
(b) Dry grinding: 0.028 g (0.0001 mmol) of Pentoxifylline and 0.012 g (0.0001 mmol) of 
benzoic acid was ground without any solvent but resulted in total conversion to 
PENBEN. (c) Slurry: 0.28 g (0.0001 mmol) of Pentoxifylline and 0.12 g of benzoic acid 
(0.001 mmol) was slurried at ca. 125 rpm in 5 mL of ethanol overnight, under ambient 
conditions. The resulting solid was filtered and the filtrate was left for slow evaporation. 
The solid shows 100% conversion to PENBEN. The filtrate from the slurry was left for 
slow evaporation and gave rise to tiny needle shaped crystals with 65% yield after 10 
days which was used for single crystal analysis.  
 
3.4.3. Pentoxifylline·1-hydroxy-2-napthoic acid, PEN1HY (1:1) 
This cocrystal was made via the following methods (a) Solvent drop grinding: 0.028 g 
(0.0001 mmol) of Pentoxifylline and 0.019g (0.0001 mmol) of 1-hydroxy-2-napthoic  
acid were ground with 50 µL of ethanol for fifteen minutes in a ball mill with two balls 
resulting in PEN1HY with approximately 100 % yield. Solvent drop grinding with water 
and DMF also resulted in PEN1HY. (b) Dry grinding: 0.028 g (0.0001 mmol) of 
Pentoxifylline and 0.019 g (0.0001 mmol) of 1-hydroxy-2-napthoic acid was ground 
without any solvent but resulted in conversion to PEN1HY. (c) Slurry: 0.28 g (0.0001 
mmol) of Pentoxifylline and 0.12 g (0.001 mmol) of 1-hydroxy-2-napthoic acid was 
slurried at ca. 125 rpm in 4 mL of acetonitrile overnight, under ambient conditions. The 
resulting solid was filtered and the filtrate was left for slow evaporation which yielded 
single crystals. The residual solid showed 100% conversion to PEN1HY. 
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3.4.4. Pentoxifylline·Salicylic acid, PENSAL (1:1) 
This cocrystal was also made via multiple methods (a) Solvent drop grinding: 0.028 g 
(0.0001 mmol) of Pentoxifylline and 0.014g (0.0001 mmol) of salicylic acid were ground 
with 50µL of ethanol, water and DMF for fifteen minutes in a ball mill with two balls 
resulting in total conversion to PENSAL. (b) Dry grinding: 0.028 g (0.0001 mmol) of 
Pentoxifylline and 0.014 g (0.0001 mmol) of salicylic acid was ground without any 
solvent but resulted in total conversion to PENSAL. (c) Slurry: 0.28 g (0.0001 mmol) of 
pentoxifylline and 0.14 g of salicylic acid (0.001 mmol) was slurried at ca. 125 rpm in 5 
mL of acetonitrile overnight, under ambient conditions. The resulting solid was filtered 
and the filtrate was left for slow evaporation. The residual solid showed 100% conversion 
to PENSAL. The filtrate from the slurry was gave rise to needle shaped crystals after 5 
days which was used for single crystal analysis.  
 
3.4.5. Pentoxifylline·Gallic acid monohydrate, PENGAL.H2O (1:1:1) 
This cocrystal was made via multiple methods (a) Solvent drop grinding: 0.028 g (0.0001 
mmol) of Pentoxifylline and 0.017g (0.0001 mmol) of gallic acid were ground with 50µL 
of ethanol, water and DMF for fifteen minutes in a ball mill with two balls resulting in 
total conversion to PENGAL. (b) Dry grinding: 0.028 g (0.0001 mmol) of Pentoxifylline 
and 0.017 g (0.0001 mmol) of gallic acid was ground without any solvent but resulted in 
total conversion to PENGAL. (c) Slurry: 0.28 g (0.0001 mmol) of Pentoxifylline and 0.17 
g of gallic acid (0.001 mmol) was slurried at ca. 125 rpm in 7 mL of water overnight, 
under ambient conditions. The resulting solid was filtered and the filtrate was left for 
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slow evaporation. The residual solid gave 100% conversion to PENGAL. The filtrate 
from the slurry was left for slow evaporation and gave rise to tiny needle shaped crystals 
after 10 days which was used for single crystal analysis.  
 
3.4.6. Pentoxifylline·Salicylamide, PENSLC (1:1) 
This cocrystal was also made via multiple methods (a) Solvent drop grinding: 0.028 g 
(0.0001 mmol) of Pentoxifylline and 0.014g (0.0001 mmol) of salicylamide were ground 
with 50µL of ethanol, water and DMF for fifteen minutes in a ball mill with two balls 
resulting in PENSLC with 100 % yield. (b) Dry grinding: 0.028 g (0.0001 mmol) of 
Pentoxifylline and 0.014 g (0.0001 mmol) of salicylamide was ground without any 
solvent but resulted in total conversion to PENSLC. (c) Slurry: 0.28 g (0.0001 mmol) of 
Pentoxifylline and 0.14 g of salicylamide (0.001 mmol) was slurried at ca. 125 rpm in 5 
mL of water overnight, under ambient conditions. The resulting solid was filtered and the 
filtrate was left for slow evaporation. The residual solid gave 100% conversion to 
PENSLC. The filtrate from the slurry was left for slow evaporation and gave rise to tiny 
needle shaped crystals after a week which was used for single crystal analysis.  
 
3.4.7. Pentoxifylline·Coumaric acid, PENCOU  
This cocrystal was made via multiple methods (a) Solvent drop grinding: 0.028 g (0.0001 
mmol) of Pentoxifylline and 0.016g (0.0001 mmol) of coumaric acid were ground with 
50µL of ethanol, water and DMF for fifteen minutes in a ball mill with two balls resulting 
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in PENCOU with total conversion. (b) Dry grinding: 0.028 g (0.0001 mmol) of 
Pentoxifylline and 0.016 g (0.0001 mmol) of coumaric acid was ground without any 
solvent but resulted in total conversion to PENCOU. (c) Slurry: 0.28 g (0.0001 mmol) of 
Pentoxifylline and 0.16 g of coumaric acid (0.001 mmol) was slurried at ca. 125 rpm in 5 
mL of water overnight, under ambient conditions. The resulting solid was filtered and the 
filtrate was left for slow evaporation. The residual solid showed 100% conversion to 
PENCOU. The filtrate from the slurry was left for slow evaporation and gave rise to 
needle shaped crystals after 6 days which was used for single crystal analysis.  
 
3.4.8. Pentoxifylline·Caffeic acid, PENCFA  
This cocrystal was made via multiple methods (a) Solvent drop grinding: 0.028 g (0.0001 
mmol) of Pentoxifylline and 0.018g (0.0001 mmol) of caffeic acid were ground with 
50µL of ethanol, DMF and water for fifteen minutes in a ball mill with two balls resulting 
in PENCFE with approximately 100 % yield. (b) Dry grinding: 0.028 g (0.0001 mmol) of 
Pentoxifylline and 0.018 g (0.0001 mmol) of caffeic acid was ground without any solvent 
but resulted in total conversion to PENCFE. (c) Slurry: 0.28 g (0.0001 mmol) of 
Pentoxifylline and 0.18 g of caffeic acid (0.001 mmol) was slurried at ca. 125 rpm in 5 
mL of ethanol overnight, under ambient conditions. The resulting solid was filtered and 
the filtrate was left for slow evaporation. The residual solid showed 100% conversion to 
PENCFE. The filtrate from the slurry gave rise to needle shaped crystals after 10 days 
which was used for single crystal analysis.  
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3.4.9. Pentoxifylline·Catechin Hydrate, PENCAT  
This cocrystal was also made via multiple methods (a) Solvent drop grinding: 0.028 g 
(0.0001 mmol) of Pentoxifylline and 0.015g (0.00005 mmol) of catechin hydrate were 
ground with 50µL of ethanol for fifteen minutes in a ball mill with two balls resulting in 
PENCAT with 100 % yield. (b) Dry grinding: 0.028 g (0.0001 mmol) of Pentoxifylline 
and 0.015 g (0.00005 mmol) of catechin hydrate was ground without any solvent but 
resulted in total conversion to PENCAT. (c) Slurry: 0.28 g (0.0001 mmol) of 
Pentoxifylline and 0.15 g of catechin hydrate (0.0005 mmol) was slurried at ca. 125 rpm 
in 5 mL of ethanol overnight, under ambient conditions. The resulting solid was filtered 
and the filtrate was left for slow evaporation. The residual solid showed 100% conversion 
to PENCAT.  
 
3.4.10. Dissolution studies on cocrystals 
Powder dissolution studies were performed on all cocrystals and pure Pentoxifylline. The 
study was performed in deionized water at room temperature. All the crystal forms were 
sieved to get consistent particle sizes between 53 -75µm as dissolution rate is affected by 
particle size. Supersaturated slurries were stirred with magnetic sir bars at a rate of 125 
rpm. Dissolution rate was determined by drawing fixed aliquots with a syringe and 
filtering through 0.45µm filters after 5, 10, 15, 20, 25, 30, 60, 120, 180, 240, and 2400 
minutes. The solutions were analyzed to determine the concentration of Pentoxifylline 
using Gas Chromatography and Mass spectrophotometer detector. The experiment was 
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done in triplicate to allow for statistical analysis. The leftover solid was characterized at 
the end of the study identify the solid phase post dissolution. 
19 
 
3.5. Results  and Discussion 
 
3.5.1. Cocrystals of Pentoxifylline  
Pentoxifylline belongs to derived class of methyl xanthenes, as mentioned before and has 
the same functional groups as them except for the side chain attachment which contains 
an extra carbonyl group. Due to the similar hydrogen bonding moieties present in it, and 
owing to the inherent capacity of methyl xanthenes to readily form hydrogen bonds with 
complementary functional groups such as carboxylic acids, flavonoids and amides as has 
been reported in the CSD for caffeine, aided in understanding supramolecular 
heterosynthons that could be formed and thus cocrystals of the API was achieved readily. 
A survey of the Cambridge Structural Database (version 5.31, update of May 2011) was 
carried out using ConQuest (version 1.12) and limited to organic molecules with 
determined 3D-coordinates and R ≤ 0.075. The survey revealed that there is just one 
entry for Pentoxifylline, JAKGEH, depicting its crystal structure shown in Figure 3.1. 
There are no other reported cocrystals of the API.  
A CSD analysis performed on the functional groups of the API has already been shown 
in the previous chapter and was used in this case too. The cocrystal formers used in this 
case study are depicted in Table 2.1, 2.2 and 2.3. 
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3.5.2.Crystal Structure Discussion : Pentoxifylline·Benzoic acid 1:1 
Pentoxifylline·Benzoic acid, PENBEN crystallizes in the space group P-1. Each 
asymmetric unit contains one Pentoxifylline and one benzoic acid molecule. Figure 3.3 
depicts the hydrogen bonding between the molecules. The molecules are discretely 
arranged in the sheet.   
 
 
Figure 3.3. The arrangement of Pentoxifylline and benzoic acid molecules in 
PENBEN reveals that it is sustained by a supramolecular heterosynthon between 
aromatic nitrogen and carboxylic acid. 
The aromatic nitrogen in imidazole ring of Pentoxifylline is seen to participate in 
hydrogen bonding with the carboxylic acid moiety of benzoic acid with a N···O distance 
of  2.751 (3) Å. This is the only synthon observed in this cocrystal. The sheets are stacked 
with the help of π-π interactions and follow the herringbone pattern as shown in Figure 
3.4. 
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Figure 3.4. Herringbone pattern observed between the sheets in PENBEN sustained 
by π-π interactions. 
3.5.3. Pentoxifylline·1-hydroxy-2-napthoic acid 1:1  
Pentoxifylline·1-hydroxy-2-napthoic acid, PEN1HY crystallizes in the space group P-1. 
Each asymmetric unit contains one molecule each of Pentoxifylline and 1-hydroxy-2-
napthoic acid. The molecules are arranged discretely. Figure 3.5 illustrates the hydrogen 
bonding between the two molecules. The aromatic nitrogen is participates in hydrogen 
bonding with carboxylic acid moiety, O···N, at a distance of 2.597 Å. Intramolecular 
hydrogn bonding is also seen to occur between the hydroxyl group of 1-hydroxy-2-
napthoic acid and carbonyl group, O···O at a distance of 2.521 Å.  The stacking of 
molecules arranged via π-π interactions are shown in Figure 3.6. A CSD search of 1-
hydroxy-2-napthoic acid cocrystals revealed that there are 3 cocrystals listed out of which 
KIGKIV and KIGLIW, cocrystals with caffeine and theophylline respectively show 
similar hydrogen bonding between the aromatic nitrogen and carboxylic acid as seen in 
PEN1HY. The third cocrystal, between carbamazepine and 1-hydroxy-2-napthoic acid 
(MOXWEC) show hydrogen bonding between carboxylic acid and amide group.  
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Figure 3.5. Hydrogen bonding between Pentoxifylline and 1-hydroxy-2-napthoic 
acid reveals that it is sustained by a supramolecular heterosynthon between 
aromatic nitrogen and carboxylic acid. Intramolecular hydrogen bonding is also 
observed between hydroxyl and carbonyl group in 1-hydroxy-2-napthoic acid. 
 
 
Figure 3.6. The stacking of PEN1HY sustained by π-π interactions. 
 
3.5.4. Pentoxifylline·Salicylic acid 1:1 
Pentoxifylline·Salicylic acid, PENSAL also crystallizes in P-1 space group. The 
asymmetric unit contains one molecule each of Pentoxifylline and salicylic acid. 
Hydrogen bonding between the molecules can be observed as shown in Figure 3.7. 
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Figure 3.7. Hydrogen bonding between Pentoxifylline and Salicylic acid sustained 
by supramolecular heterosynthon between aromatic nitrogen and carboxylic acid. 
The molecules are arranged in discrete tapes in the sheet. Aromatic nitrogen of the is seen 
to participate in hydrogen bonding with the carboxylic acid moiety of salicylic acid, 
O···N at a distance of 2.648(4) Å. Salicylic acid also is involved in intramolecular 
hydrogen bonding between the carbonyl group and hydroxyl group , O···O, at a distance 
of  2.579(3) Å. Tapes of the molecules arranged and sustained by .π-π interactions as seen 
in Figure 3.8. A CSD search of salicylic acid reveals 8 cocrystals sustained by the same 
heterosynthon (aromatic nitrogen and carboxylic acid) as seen in case of PENSAL. 
 
 
Figure 3.8. The arrangement of PENSAL in the crystal lattice. Stacking of the 
cocrystal is achieved with the help of π-π interactions. 
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3.5.5. Pentoxifylline. Gallic acid monohydrate 1:1:1 
Pentoxifylline∙Gallic acid, PENGAL.H2O crystallizes in monoclinic space group P21/n. 
Each asymmetric unit contains one molecule each of Pentoxifylline, gallic acid and 
water. Aromatic nitrogen of Pentoxifylline engages in supramolecular heterosynthon with 
the carboxylic acid moiety of gallic acid, O∙∙∙N, at a distance of 2.705(4) Å. The carbonyl 
group on the side chain of Pentoxifylline engages in hydrogen bonding with hydroxyl 
groups in the meta and para position of gallic acid, O∙∙∙O at distances of 2.785(3) Å and 
2.716(3) Å respectively. These interactions are illustrated in Figure 3.9 with the hydroxyl 
group in the para position of gallic acid also hydrogen bonds to the carbonyl group 
adjacent to the methyl group in the benzene ring in Pentoxifylline, O∙∙∙O at a distance of 
2.672(3) Å.   
 
Figure 3.9. Interactions between Pentoxifylline and gallic acid molecules in 
PENGAL.H2O reveals supramolecular heterosynthon between aromatic nitrogen 
and carboxylic acid.   
The hydroxyl group on the ortho position of gallic acid is seen to participate in hydrogen 
bonding with the water molecule as can be seen in Figure 3.10 below. The hydrogen 
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bond distances observed in this tetramer are , O∙∙∙O , 2.668(3) Å and 2.741(3) Å. Another 
tetrameric structure formed between water and carbonyl group next to the imidazole ring 
of Pentoxifylline is shown in Figure 3.11 below with bond distance of, O∙∙∙O at 2.818(3) 
Å.  
There are 7 cocrystals of gallic acid reported in the CSD. It has been seen that in case of 
caffeine·gallic acid hemihydrates cocrystal (MUPNOB) the hydrogen bonding occurs 
between the acid and aromatic nitrogen moiety as seen in IV but in case of gallic 
acid·theobromine dihydrate cocrystal aromatic nitrogen hydrogen bonds to the water 
molecule. Other cocrystals involve bonding between other functional groups and are seen 
to form the acid···amide dimer (MUPPAP) or acid···acid dimer (RUWFOF, RUWGUM).  
 
 
Figure 3.10.  The tetramer observed between water and gallic acid molecule in 
PENGAL.H2O formed between hydroxyl group of the gallic acid molecule and 
water.  
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Figure 3.11.  The tetramer observed between water and Pentoxifylline molecule in 
PENGAL. H2O formed between carbonyl group of Pentoxifylline and water.  
3.5.6. Pentoxifylline·Salicylamide 1:1 
Pentoxifylline.Salicylamide, PENSLC (V) also crystallizes in P-1 space group. Each  
asymmetric unit contains one Pentoxifylline and one salicylamide molecule. The 
hydrogen bonding observed between the molecules is shown in Figure 3.12. The 
molecules are discretely arranged in the sheet. 
 
 
Figure 3.12. The hydrogen bonding between Pentoxifylline and Salicylamide reveals 
the formation of an amide amide dimer(supramolecular homosynthon) as opposed 
to a heterosynthon.  
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In this cocrystal the amide moiety of the salicylamide molecule is seen to participate in a 
homosynthon by forming the amide amide dimer with another salicylamide molecule, 
N∙∙∙O at a distance of 2.831(2) Å and 2.915(2) Å instead of forming the acid-amide 
heterosynthon. Salicylamide also is seen to participate in intramolecular hydrogen 
bonding between its carbonyl and hydroxyl group, O∙∙∙O at a distance of 2.538(1) Å. 
Figure 3.13 depicts the stacking of each sheet of the cocrystal sustained by π-π 
interactions. 
There is just one reported cocrystal of salicylamide in the CSD and also involves 
formation of an amide···amide dimer as seen in this case.  
 
 
3.13. The stacking of PENSLC is sustained by π-π interactions. 
3.5.7. Pentoxifylline·Catechin Hydrate 
This cocrystal was prepared via various methods in a 1:1 ratio as has been mentioned in 
the experimental section and characterized via PXRD. But efforts to prepare single 
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crystals did not yield any results as of yet.  The powder of the cocrystal was used for 
crystal data analysis and though the structure has not been solved yet, it has been indexed 
to P21.  
In case of catechin hydrate, only the crystal structure of catechin hydrate (LUXWOR) is 
reported as mentioned before, no cocrystals of catechin hydrate are reported making this 
one the second reported cocrystal after the one with caffeine. 
 
3.5.8. Pentoxifylline·Coumaric acid , Pentoxifylline·Caffeic acid 
These cocrystals was prepared via various methods in a 1:1 ratio as has been mentioned 
in the experimental section and characterized via PXRD. But efforts to prepare single 
crystals did not yield any results as of yet.   
 
3.5.9. Dissolution and Solubility Studies  
Dissolution studies were performed on the API  and all the cocrystals. Following 
dissolution studies, the concentration vs. time graph was generated for a time period of 24 
hours. For purposes of clarity, the time point for the 24
th
 hour reading was changed to 
480 minutes. Pentoxifylline’s solubility was found to be 76 mg/mL which is in agreement 
with the literature reported solubility value. 
2
 The dissolution profiles have been divided 
into two figures for clarity. Figure 3.14 illustrates the solubility profiles for Pentoxifylline 
and all its cocrystals; Figure 3.15 illustrates the solubility profile for cocrystals in the 
solubility range of 1-10 mg/mL.  
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3.14 Dissolution profiles in water for 24 hours for Pentoxifylline and its cocrystals. 
From the graph it can be seen that PENBEN showed maximum concentration of 8.2 mg 
/mL. PEN1HY achieved maximum concentration of 1 mg/mL by the end of 24 hours. 
PENSAL’s dissolution profile also shows a smooth plateau in the curve with maximum 
concentration at 9 mg/mL. PENGAL shows a maximum concentration of 2.5 mg/mL 
also show smooth plateau like profile. PENSLC, PENCOU, PENCFA, and PENCAT 
reach concentration of 20 mg/mL, 4.7 mg/mL, 1.25 mg/mL and 0.8 mg/mL respectively 
by the end of 24 hours.  
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This solubility data is critical in pointing that an API with very high solubility can be 
manipulated with cocrystallization with novel crystal forms.  
The PXRD and DSC’s of the residual solids were done after the study at the end of 
twenty four hours and it was found that the all the cocrystals were stable till that the time 
period.  
 
 
3.15. Dissolution profiles in water for cocrystals PENCOU, PENSAL, PENCFE, 
PENGAL.H2O, PENBEN, PEN1HY and PENCAT (solubility range 1-10 mg/mL). 
These results show that all the cocrystals, can be used as an alternative form of the API as 
the solubility of API in the cocrystals have decreased, and thus using these forms for 
sustained release dosage is promising. 
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3.5.10. Correlation between Solubility and Melting Point  
The cocrystal formers used in the study can be classified into the following classes as 
shown in Table 3.1. 
Table 3.1. Classification of cocrystal formers 
Hydroxycinnamic 
acid 
Carboxylic 
acid 
Phenolic 
acid 
Flavonoid Amide 
Coumaric acid 1-hydroxy-2 
napthoic acid 
Gallic acid Catechin 
hydrate 
Salicylamide 
Caffeic acid Benzoic acid Salicylic 
acid 
  
 
As shown with caffeine in the previous chapter, the correlation between solubility and 
melting point is a vital analysis in terms of correlating calculable physicochemical 
property with solubility for thermodynamically stable cocrystals. Generally higher the 
melting point lower is the solubility and vice versa. Here again on correlating log of 
solubility (to make the points appear closer) and onset of melting point of cocrystal 
illustrated in Figure 3.16, shows that there is no concrete relationship between these two 
parameters (22%), which is in consensus with Bak et al’s conclusion 9(d) and also what 
was observed with caffeine’s cocrystals. 
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Figure 3.16. Solubility of cocrystals shows no relationship with melting point 
probably due to the variability in coformers used. 
When looked within specific classes of compounds, in case of caffeine cocrystals a very 
high correlation was observed (85 %) with the hydroxycinnamic acids but since the data 
set here is smaller, that area was not investigated here as the data would be inconclusive.  
Table 3.2 below lists the melting points of the cocrystal and the cocrystal formers in this 
study. 
Table 3.2. Melting points of the cocrystal formers and the cocrystals 
COCRYSTAL /COMPOUND M.P. of compound/ 
cocrystal (⁰ C) 
M.P of 
CCF (⁰ C) 
Pentoxifylline 110   
PENBEN 91   121 
PEN1HY 124 195 
PENSAL 98 158 
PENGAL.H2O 188 268 
PENSLC 103 140 
PENCOU 128 214 
PENCFE 150 211 
PENCAT 169 214 
(* Melting points were taken from scifinder.org) 
R² = 0.2155
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3.5.11. Relationship between solubility and crystal packing efficiency  
Crystal packing as discussed previously is a important parameter for crystalline 
compounds. The way a molecule packs in a crystal , allows for different properties of 
compounds to be expressed. For organic molecules packing efficiency is found to be in 
the range of 0.65-0.77. Though a small range, it was seen in the previous chapter that it 
can be critical in demonstrating solubility patterns. The software Platon 
22
 was used to 
calculate the Kitaigorodskii 
21
 packing efficiency. Table 3.3 lists the crystal packing 
efficiency and solubility of cocrystals with crystal structures solved. We found that for 
caffeine cocrystals, highest solubility was related to the lowest efficiency and vice versa 
thereby showing that crystal packing does have a role to play in cocrystal solubility. For 
this data set however we explored this arena again and found no correlation (7%) as seen 
in Figure 3.17. Thus though, crystal packing efficiency is an important parameter, for this 
dataset, a conclusion cannot be made.   
Table 3.3. Crystal packing efficiency and solubility of Pentoxifylline and its 
cocrystals 
 Compound/Cocrystal 
Crystal packing efficiency 
(%) Solubility(mg/ml) 
Pentoxifylline 70.7 76.1 
PENBEN 71.7 8.18 
PEN1HY 68.8 1.03 
PENSAL 69.9 9.03 
PENGAL.H2O 72.1 2.46 
PENSLC 71 19.88 
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Figure 3.17. Crystal packing efficiency on correlation with cocrystal solubility shows 
no correlation. 
3.5.12. Correlation between solubility of cocrystal former to solubility of cocrystal 
As seen for caffeine, the collected data here also shows that there has been a decrease in 
the solubility of the API through cocrystallization and in this context the above 
parameters were correlated to determine any relationship between them as shown in 
Figure 3.18 It is seen that there is a general trend of decrease in Pentoxifylline solubility 
in the cocrystals as seen with caffeine cocrystals. But still there is no correlation observed 
that could help in prediction of solubility, thereby suggesting that solubility of cocrystal 
former is not directly proportional to cocrystal solubility. 
 
R² = 0.07
0
10
20
30
40
50
60
70
80
68.5 69 69.5 70 70.5 71 71.5 72 72.5
S
o
lu
b
il
it
y
Crystal packing efficiency (%)
   
86 
 
 
Figure 3.18. On correlation cocrystal former solubility and cocrystal solubility no 
correlation other than a general decrease is observed in cocrystal solubility. 
3.5.13. Modification of solubility of Pentoxifylline following cocrystallization 
The experimental solubility of API in its cocrystals was compared to the measured 
solubility of the API. The results are shown in the Table 3.4 below.  
Table 3.4. Solubility modification of Pentoxifylline in its cocrystals 
Cocrystal  With  respect to Pentoxifylline 
(decrease)  
PENBEN -9 fold 
PEN1HY -74 fold  
PENSAL -8 fold  
PENGAL.H2O -31 fold 
R² = 0.5076
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PENSLC -4 fold 
PENCOU -99 fold 
PENCFE -61 fold 
PENCAT -16 fold  
 
As seen from the table, the maximum decrease of solubility of the API is around 99 folds 
and is achieved by PENCOU. 
 
3.6. Conclusion 
In summary, as shown earlier with caffeine and other examples from the literature, 
pharmaceutical cocrystals can modify physicochemical properties of an API. This 
statement is exemplified again by the case study presented here where the cocrystals of 
Pentoxifylline lowered the solubility of the API, allowing for the potential of a slow 
release form of the drug.   Eight new cocrystals of were made and their solubility in water 
was analyzed.  
All of them were found to be thermodynamically stable after twenty-four hours. The 
dissolution profiles showed that PENCOU had achieved the lowest concentration of 0.7 
mg/mL and PENSLC the highest. The effects of melting point, solubility of cocrystal 
former and crystal packing efficiency upon solubility were also investigated as was done 
for caffeine cocrystals. It was seen that, in general, melting point could not be correlated 
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as a function of solubility, and due to the small dataset, correlations amongst specific 
class of compounds were not made as that would render inconclusive analysis. 
As done previously, solubility as a function of crystal packing efficiency was analyzed 
and it was found, that no correlation occurs between solubility and packing efficiency; 
This shows that though property could be important and help in future understanding of 
cocrystal solubility, at least in this case its role was not evident.  
For relation between the cocrystal former and cocrystal solubility, a general trend was 
observed, where for coformers used herein with solubility lower than Pentoxifylline , 
gave an overall  decrease in the solubility of the pure API with the maximum being a 99 
fold decrease but like caffeine cocrystals no specific relationship between them could  be 
established.  
Pentoxifylline’s solubility was thus successfully lowered through cocrystallization with 
nutraceutical or pharmaceutically acceptable compounds. Predictability of the resultant 
solubility through melting point or coformer solubility correlation or crystal packing 
efficiency was not successful.  
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4. CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS 
 
Pharmaceutical cocrystals, an emerging class of compounds have the capacity to modify 
physicochemical properties of a compound without affecting its biological activity and 
in turn afford crystalline compounds. Herein two API’s, caffeine and Pentoxifylline 
were targeted as case studies.  
Caffeine was targeted for cocrystallization for its possible clinical use for Alzheimer’s 
disease. In the case, caffeine was cocrystallized with cyanuric acid, chlorogenic acid, 
syringic acid and catechin hydrate using statistics from the CSD. Following synthesis, 
dissolution studies were performed on a set of 12 cocrystals which included reported 
forms from the literature and the ones which were newly synthesized, for a period of 24 
hours in deionized water at room temperature. Particle size was controlled by sieving.  
All the cocrystal formers had solubility lower than that of caffeine. Dissolution studies 
showed a marked decrease in caffeine solubility in its cocrystals. Powder XRD done at 
the end of 24 hours on the leftover solid confirmed that all the cocrystals were 
thermodynamically stable. This data is critical in pointing out that solubility can be 
decreased using cocrystals. The smooth plateau like curves achieved by the cocrystals 
showcase constant dissolution rate and hence potential for a sustained dosage. Future 
directions would involve in vivo studies to make this an achievable objective. Various 
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analyses were also made between cocrystal solubility and melting point, crystal packing 
efficiency and cocrystal former solubility.  
Pentoxifylline, a drug which contraindicated for use in autism has a low half life. This 
drug was targeted for cocrystallization to see if cocrystals can achieve lower solubility 
and a dissolution rate such that the half life can be modified to get a sustained dosage 
form. The coformers used in the study were benzoic acid, salicylic acid, 1-hydroxy-2-
napthoic acid, gallic acid, coumaric acid, caffeic acid, catechin hydrate and salicylamide. 
The dissolution  study conditions were similar to that of caffeine and powder XRD done 
at the end of the study confirmed stability of the cocrystals. The smooth plateau like 
curves achieved by these cocrystals also, showcase constant dissolution rate and hence 
potential for a sustained dosage form. 
In both the cases, the cocrystals had achieved lower solubility as compared to the 
respective API’s and the conformers too were of solubility lower than that of each, thus 
cocrystal former solubility was correlated with cocrystal solubility to see if any 
correlation exists in this regard. It was seen that no correlation exists between these 
parameters in both the cases suggesting that solubility prediction is not possible.  
Solubility of cocrystals in both cases was correlated with melting point and it was seen 
that no correlation could be established in either case. Thus tailoring solubility by 
prediction of melting point before synthesis is still an elusive situation and more studies 
would be required to make a conclusion. 
Crystal packing efficiency was correlated with solubility of cocrystal and in case of 
caffeine cocrystals it was seen that a 41% correlation existed and the highest crystal 
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packing efficiency was achieved by CAFELA which had the lowest solubility and vice 
versa. In case of Pentoxifylline though this correlation did not exist suggesting that 
though crystal packing efficiency seems to be an important parameter but a conclusion 
in this case cannot be made. 
Thus in conclusion, CAFELA.H2O achieved a 278 fold decrease in caffeine solubility 
and PENCOU a 99 fold decrease in Pentoxifylline solubility. It is hence understandable 
that pharmaceutical cocrystals are versatile and can help modifying properties and 
successfully shows the significance of making “crystals with a purpose”. 
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APPENDIX A: EXPERIMENTAL DATA 
 
The experimental data was collected using DSC (TA instrument 2920), FT-IR (Nicolet 
Avatar 320 FTIR, solid state), Powder X-ray diffraction (Bruker AXS D8, Cu radiation ), 
TGA (STM6000).  
 
1.1. Experimental data for Caffeine·Cyanuric acid monohydrate, CAFCYA.H2O 
2:1:1 
Data includes DSC thermogram for caffeine∙cyanuric acid monohydrate,  DSC 
thermogram for caffeine∙cyanuric acid anhydrate got after heating the monohydrate 
for 1 day,  FT-IR spectrum of the cocrystal, comparison between calculated (from 
single crystal data)  and experimental powder patterns (from bulk sample)  and TGA 
data for the cocrystal monohydrate.  
 
 
Figure A1. DSC thermogram of CAFCYA.H2O 
   
98 
 
APPENDIX A (Continued) 
 
Figure A2. DSC thermogram of CAFCYA anhydrate. 
 
 
Figure A3. FT-IR of CAFCYA.H2O. 
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APPENDIX A (Continued) 
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Figure A4. PXRD comparison of CAFCYA.H2O. 
 
 
Figure A5. TGA Data of CAFCYA.H2O. 
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APPENDIX A (Continued) 
1.2. Experimental data for Caffeine·Syringic tetrahydrate, CAFSYR.4H2O 1:1:4 
Data includes DSC thermogram for caffeine∙syringic acid tetrahydrate, FT-IR 
spectrum of the cocrystal, comparison between calculated (from single crystal data) 
and experimental powder patterns (from bulk sample)  and TGA data for the 
cocrystal. 
 
Figure A6. DSC thermogram of CAFSYR.4H2O. 
 
 
Figure A7. FT-IR of CAFSYR.4H2O. 
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APPENDIX A (Continued) 
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Figure A8. PXRD comparison of CAFSYR.4H2O. 
 
 
 
Figure A9. TGA Data of CAFSYR.4H2O. 
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APPENDIX A (Continued) 
1.3. Experimental data for Caffeine·Chlorogenic Acid, CAFCGA  
Data includes DSC thermogram for caffeine∙chlorogenic acid, FT-IR spectrum of the 
cocrystal, comparison between powder patterns of the starting materials and the 
cocrystal and TGA data for the cocrystal. 
  
 
Figure A10. DSC thermogram of CAFCGA . 
 
 
 
Figure A11. FT-IR of CAFCGA. 
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APPENDIX A (Continued) 
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Figure A12. PXRD Comparison of CAFCGA. 
 
 
 
Figure A13. TGA Data of CAFCGA. 
   
104 
 
APPENDIX A (Continued) 
1.4. Experimental data for Caffeine·Catechin Hydrate, CAFCAT 
Data includes DSC thermogram for caffeine∙catechin hydrate, FT-IR spectrum of the 
cocrystal, comparison between powder patterns of the starting materials and the 
cocrystal. 
 
 
Figure A14. DSC thermogram of cocrystal of CAFCAT. 
 
 
Figure A15. FT-IR of CAFCAT. 
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APPENDIX A (Continued) 
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Figure A16. PXRD Comparison of CAFCAT. 
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APPENDIX A (Continued) 
1.6. Experimental data for Pentoxifylline∙Benzoic acid, PENBEN 1:1 
Data includes DSC thermogram for pentoxifylline∙benzoic acid, FT-IR spectrum of 
the cocrystal, comparison between calculated (from single crystal data) and 
experimental powder patterns (from bulk sample) and TGA data for the cocrystal. 
 
 
Figure A17. DSC thermogram of PENBEN. 
 
 
 
Figure A18. FT-IR of PENBEN. 
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APPENDIX A (Continued) 
 
Figure A19. TGA Data of PENBEN. 
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Figure A20. PXRD Comparison of PENBEN. 
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APPENDIX A (Continued) 
1.7. Experimental data for Pentoxifylline∙1-hydroxy-2-napthoic acid, PEN1HY  1:1 
Data includes DSC thermogram for pentoxifylline∙1-hydroxy-2-napthoic acid, FT-IR 
spectrum of the cocrystal, comparison between calculated (from single crystal data)  
and experimental powder patterns (from bulk sample)  and TGA data for the 
cocrystal. 
 
 
Figure A21. DSC thermogram of PEN1HY. 
 
 
Figure A22. FT-IR of PEN1HY. 
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APPENDIX A (Continued) 
 
Figure A23. TGA Data of PEN1HY. 
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Figure A24. PXRD Comparison of PEN1HY. 
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APPENDIX A (Continued) 
1.8. Experimental data for Pentoxifylline∙Salicylic acid, PENSAL 1:1 
Data includes DSC thermogram for pentoxifylline∙salicylic acid, FT-IR spectrum of 
the cocrystal, comparison between calculated (from single crystal data)  and 
experimental powder patterns (from bulk sample)  and TGA data for the cocrystal. 
 
Figure A25. DSC thermogram of PENSAL. 
 
 
Figure A26. FT-IR of PENSAL. 
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Figure A27. TGA Data of PENSAL. 
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Figure A28. PXRD Comparison of PENSAL. 
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APPENDIX A (Continued) 
1.9. Experimental data for Pentoxifylline∙Gallic acid, PENGAL.H2O 1:1:1  
Data includes DSC thermogram for pentoxifylline∙gallic acid, DSC of the anhydrate 
of the cocrystal, comparison between calculated (from single crystal data) and 
experimental powder patterns (from bulk sample) and TGA data for the cocrystal. 
 
 
Figure A29. DSC thermogram of PENGAL.H2O. 
 
 
Figure A30. DSC thermogram of cocrystal anhydrate. 
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APPENDIX A (Continued) 
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Figure A31. PXRD Comparison of PENGAL.H2O. 
 
 
 
Figure A32. TGA Data of PENGAL.H2O. 
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APPENDIX A (Continued) 
1.10. Experimental data for Pentoxifylline∙Salicylamide, PENSLC 1:1  
Data includes DSC thermogram for pentoxifylline∙salicylamide , FT-IR spectrum of 
the cocrystal, comparison between calculated (from single crystal data)  and 
experimental powder patterns (from bulk sample)  and TGA data for the cocrystal. 
 
 
Figure A33. DSC thermogram of cocrystal of PENSLC. 
 
 
Figure A34. FT-IR of PENSLC. 
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APPENDIX A (Continued) 
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Figure A35. PXRD Comparison of PENSLC. 
 
 
 
Figure A36. TGA Data of PENSLC. 
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APPENDIX A (Continued) 
1.11. Experimental data for Pentoxifylline∙Coumaric acid, PENCOU  
Data includes DSC thermogram for pentoxifylline∙coumaric acid, FT-IR spectrum of 
the cocrystal, comparison between powder patterns of the starting materials and the 
cocrystal and TGA data for the cocrystal. 
 
 
Figure A37. DSC Thermogram of PENCOU. 
 
  
   
117 
 
 
Figure A38. FT-IR of PENCOU. 
 
 
0 5 10 15 20 25 30 35 40 45
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2.2
2.4
2.6
PENTOXIFYLLINE
COUMARIC ACID
PENCOU
COUMARIC ACID MONOHYDRATE
R
E
L
A
T
IV
E
 I
N
T
E
N
S
IT
Y
2 THETA
 
Figure A39. PXRD Comparison of PENCOU. 
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Figure A40. TGA Data of PENCOU. 
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APPENDIX A (Continued) 
1.12. Experimental data for Pentoxifylline∙Caffeic acid, PENCFA  
Data includes DSC thermogram for pentoxifylline∙coumaric acid, FT-IR spectrum of 
the cocrystal, comparison between powder patterns of the starting materials and the 
cocrystal and TGA data for the cocrystal. 
 
 
Figure A41. DSC Thermogram of PENCFA. 
 
 
 
Figure A42. FT-IR of PENCFA. 
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Figure A43. TGA Data of PENCFA. 
 
 
 
 
 
 
 
 
 
Figure A44. PXRD comparison of PENCFA. 
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APPENDIX A (Continued) 
1.13. Experimental data for Pentoxifylline∙Catechin hydrate, PENCAT  
Data includes DSC thermogram for pentoxifylline∙catechin hydrate, FT-IR spectrum 
of the cocrystal, comparison between powder patterns of the starting materials and the 
cocrystal and TGA data for the cocrystal. 
 
 
Figure A45. DSC Thermogram of PENCAT. 
 
 
Figure A46. FT-IR of PENCAT. 
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APPENDIX A (Continued) 
 
 
 
 
 
 
     
 
Figure A47. PXRD comparison of PENCAT. 
 
 
Figure A48. TGA Data of PENCAT. 
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APPENDIX B : CRYSTALLOGRAPHIC DATA 
Table B1. Hydrogen bond distances and parameters for the novel cocrystals of 
caffeine presented herein 
Compound Hydrogen Bond d (H•••A) /Å D (D∙∙∙A)/Å θ /º 
CAFCYA.
H2O 
N-H•••N 1.98 2.913(5) 160.5 
N-H•••N 2.07 2.953(5) 156 
N-H•••O 1.71 2.712(4) 
168.4 
 
O-H•••O 1.84 2.791(5) 
162.3 
 
O-H•••O 2.07 2.753(4) 146.9 
CAFSYR. 
4H2O 
 
O-H•••O 2.02 2.8(4) 155.1 
O-H•••O 2.21 2.7(4) 114.6 
O-H•••O 1.76 2.6(4) 164.8 
O-H•••O 2(3) 2.8(6) 148 
O-H•••O 2(3) 2.8(4) 155 
O-H•••N 1.9(15) 2.8(5) 174 
O-H•••O 2(3) 2.9(5) 153 
O-H•••O 1.88 2.7(5) 163.6 
O-H•••O 1.8(13) 2.6(5) 170 
O-H•••O 2(4) 2.8(5) 142 
 
The space group and cell parameters of caffeine∙catechin hydrate were determined but the 
crystal structure of could not determined.  
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APPENDIX B (Continued) 
Table B2. Crystallographic data and structure refinement parameters for the 
caffeine cocrystals reported herein 
 CAFCYA.H2O       CAFSYR.4H2O CAFCAT 
Formula 
 
C19 H25 N11 O8 
 
C17 H28 N4 O11 
 
MW 
 
535.50 
 
   464.43 
 
Crystal system Monoclinic Orthorhombic  Orthorhombic 
Space group P21/n Fdd2 
P212121 
a  (Å) 9.174(2) 30.278(5) 5.03 
b (Å) 12.991(4) 41.759(7) 12.56 
c (Å) 19.286(6) 6.7523(12) 34.13 
α (deg) 90 90  
β (deg) 103.237(13) 90  
γ (deg) 90 90  
V / A
3
 2237.5(12) 8537(3)  
Dc/g cm
-3
 1.590 1.445  
Z 4 16  
2θ range 4.14 to 67.72° 3.61 to 66.80°  
Nref./Npara 
3834/ 354 
 
3322 / 313 
 
 
T /K 105(2) 0.0336  
R1 [I>2σ (I)] 0.0756 0.0878 
 
wR2 
0.1895 
 
1.026  
GOF 
1.080 
 
 1.046 
 
Abs coef 1.083 0.923  
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APPENDIX B (Continued) 
Table B3.Crystallographic data and structure refinement parameters for the 
Pentoxifylline cocrystals reported herein 
 PENBEN       PENSAL PENGAL.H2O PENSLC 
Formula 
 
C20 H24 N4 O5 
 
C20 H24 N4 O6 C20 H26 N4 O9 C20 H25 N5 O5 
MW 
 
400.43 
 
416.43 466.45 415.45 
Crystal 
system 
Triclinic Triclinic Monoclinic Triclinic 
Space group P-1 P-1 P21/n P-1 
a  (Å) 13.3080(4) 6.6579(12) 6.728(1) 7.7991(6) 
b (Å) 13.3931(4) 8.4161(16) 12.649(2) 11.1913(8) 
c (Å) 13.8838(4) 19.325(4) 25.192(3) 12.6449(9) 
α (deg) 64.4(2) 83.603(12) 90 69.051(4) 
β (deg) 81.171(2) 82.659(12) 96.811(5) 79.322(4) 
γ (deg) 60.425(2) 70.944(11) 90 78.760(5) 
V / A
3
 1935.25(11) 1012.3(3) 2128.9(5) 1002.87(13) 
Dc/g cm
-3
 1.374 1.366 1.455 1.376 
Z 4 2 4 2 
2θ range 3.54 to 65.82° 2.31 to 65.37° 3.53 to 65.95° 3.77 to 65.91° 
Nref./Npara 
6383/531 
 
3280/276 
 
3615/311 
 
3338/281 
 
T /K 100(2) 100(2) 100(2) 100(2) 
R1 [I>2σ (I)] 0.0588 0.0582 0.0553 0.0368 
wR2 
0.1414 
 
0.1361 0.1345 0.0965 
GOF 
1.025 
 
 0.983 1.009 1.034 
Abs coef 0.832 0.855 0.985 0.837 
 
 
